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ABSTRACT
The mammalian polyamine transport system (PTS) has been of interest due to its roles in
cancer and maintaining cellular homeostasis. Polyamines are essential growth factors which are
tightly controlled via a balance of biosynthesis, metabolism, import, and export. This work
focused on the development and biological testing of polyamine transport probes to help
understand the molecular requirements of the PTS. This was mediated through the use of a CHO
(PTS active) and CHO-MG* (PTS deficient) screen, where compounds demonstrating high
toxicity in CHO and low toxicity in CHO-MG* were considered PTS selective.
The first chapter focused on the development of polyamine-based drugs which are both
metabolically stable to polyamine oxidase (PAO) activity and are hyperselective for targeting the
PTS. This approach was optimized by combining a di-substituted aryl design with terminal Nmethylation of the appended polyamine chains to generate a new class of superior PTS agonists.
The metabolic stability of these compounds was demonstrated in CHO and CHO-MG* in the
presence and absence of a known PAO inhibitor, aminoguanidine (AG). Highly PTS selective
compounds were then tested in the NCI-60 cell line screen to demonstrate the effectiveness of
polyamine-based drugs in cancer therapy. During this screen, the MALME-3M (human
melanoma) cell line was identified as being very sensitive to these PTS targeting drugs. Further
studies using MALME-3M and its normal counterpart, MALME-3, showed excellent targeting
of the cancer line over MALME-3. For example, The MeN44Nap44NMe compound showed 59fold higher toxicity in MALME-3M over MALME-3.
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The second chapter focused on the development of potential polyamine transport
inhibitors (PTIs) for use in combination therapy with α-difluoromethylornithine (DFMO). This
therapy is predicated upon reducing sustained polyamine depletion within cells by inhibiting
both polyamine biosynthesis with DFMO and polyamine transport with the PTI ligand. Potential
PTIs were identified by blocking the uptake of spermidine in DFMO-treated CHO and L3.6pl
cells. Previous work has identified a tri-substituted polyamine-based design as an effective PTI.
Low toxicity and a low Ki value in a L1210 screen were good predictors for PTI efficacy. The
structural requirements for a potent PTI were explored by modulating the toxicity through the
introduction of amide bonds, and also by determining the number and orientation of the
polyamine messages (appended to an aryl core) required for efficient inhibition of polyamine
uptake. These experiments showed that a tri-substituted design and a triamine message
(homospermidine) appended was optimal for PTI potency.
The final chapter focused on the development of Dihydromotuporamine C derivatives as
non-toxic anti-metastatic agents. Dihydromotuporamine C demonstrated good anti-invasive
properties with tumor cells. Derivatives were made in an effort to reduce the cytotoxicity of the
parent and improve the anti-migration potency. The motuporamine derivatives all have a
polyamine message (norspermidine or homospermidine) appended to make a macrocycle core,
making them prime targets to evaluate as potential PTS ligands in the CHO and CHO-MG*
screen. Each compound was also tested in the highly metastatic pancreatic cancer cell line L3.6pl
to determine both its IC50 value and maximum tolerated dose (MTD). The anti-migration assay
was performed at the lowest MTD obtained (0.6 µM) in order to compare the series at the same
non-toxic dose. The results suggested that as the N1-amine center was moved further from the
iv

macrocyclic ring, an increased ability to inhibit cell migration and reduced toxicity was
observed.
These collective findings provide new tools for cell biologists to modulate and target
polyamine transport in mammalian cells. Future applications of these technologies include new
cancer therapies which are cell-selective and inhibit the spread of tumors.
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CHAPTER I: DEVELOPMENT OF HYPERSELECTIVE POLYAMINE
TRANSPORT LIGANDS AND SELECTIVITY AGAINST SPECIFIC
HUMAN CANCERS
I.1 Abstract
The absolute cellular requirement for polyamine growth factors makes maintenance of
polyamine homeostasis critical for life. Polyamine homeostasis is accomplished via a balance of
polyamine biosynthesis, degradation, and transport. Rapidly-dividing cancer cells have been
shown to have high polyamine transport activity compared to normal cells, likely due to their
high requirement for polyamine growth factors. Therefore, the polyamine transport system (PTS)
is a therapeutically relevant target as it can provide selective drug delivery to cancer cells. This
chapter describes the synthesis and biological evaluation of new multimeric polyamine
derivatives as efficient PTS ligands. A series of arylmethyl-polyamine derivatives were
synthesized and evaluated for their ability to target the polyamine transport system. The
architectures of these probes addressed two caveats in PTS drug design: a) PTS selectivity and b)
metabolic stability to amine oxidases.
I.2 Introduction
Polyamines (1-3) are low molecular weight aliphatic amines and are essential growth
factors for cells.1 Polyamines play essential roles in transcription, translation, and chromatin
remodeling.2 Tumor cells have been shown to contain elevated polyamine levels and have active
polyamine transport systems to import exogenous polyamines.1a This special characteristic of
cancer cells allows for cell selective drug delivery of polyamine-drug conjugates to particular
cell types.1, 3 The polyamine transport system (PTS) is an important target as many cancer cells
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need to import polyamines in order to sustain their growth rate, especially in the presence of
polyamine biosynthesis inhibitors like difluoromethylornithine (DFMO). 1, 3 DFMO resembles
the natural substrate ornithine for ornithine decarboxylase (ODC), a key enzyme in putrescine (1)
biosynthesis.1, 3
Although the PTS has been recognized as an important target for cell selective drug
delivery, the PTS is still poorly understood. What is known is that the PTS is an energy-requiring
and carrier mediated process.4 Recently, two models of mammalian polyamine transport have
been proposed by Poulin5 and Belting6, respectively. Poulin suggested that polyamines enter the
cell through an active plasma membrane transporter, followed by the sequestration into
polyamine sequestering vesicles (PSVs).5a In order for polyamines to internalize within these
PSVs, a vesicular H+/polyamine carrier is needed to facilitate the import and escape from the
PSV.5a It was also found that the PSVs colocalized with acidic vesicles of the late endocytic
compartment and the trans Golgi.5a Belting, on the other hand, provided a multi-step endocytic
process where polyamines bind to heparan sulfate proteoglycans in caveolae.6b Once the
polyamines have bound to heparan sulfate, they are then endocytosed via a caveolin-dependent
process and their heparan sulfate chains are subsequently cleaved and further processing by NO
liberates the polyamines.6b
Drug conjugates, which join a cytotoxic agent to a polyamine, have exhibited selective
cytotoxicity to cancer cells compared to their normal cell counterparts.1, 3 A method was
developed to investigate if polyamine-drug conjugates were indeed targeting the polyamine
transport system. Delcros et.al. demonstrated that the Chinese hamster ovary (CHO) cell line was
very effective in identifying drug conjugates which are PTS selective.7 This cell line was chosen
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along with its transport deficient mutant (CHO-MG) in order to demonstrate which drug
conjugates selectively target the PTS.3g, 7 The CHO-MG cell line developed by Flintoff et.al.8 is
polyamine transport deficient and was developed by treating the CHO cell line with ethyl
methanesulfonate and subsequent dosing of the surviving cells with cytotoxic methylglyoxalbis(guanylhydrazone) (MGBG, a known PTS ligand) to determine their resistance.8b The
surviving cells that were found to be resistant to MGBG were also found to have a marked
decrease (less than 1% as compared to the wild type) in the uptake of radiolabeled spermidine,
demonstrating a defective PTS.8b When evaluating the polyamine drug conjugates, the respective
IC50 values are determined in CHO and CHO-MG, and the ratio (CHO-MG IC50/CHO IC50) is
used to represent the PTS selectivity of the compound. Compounds with high CHO-MG/CHO
IC50 ratios are considered PTS selective.

Figure I-1. Structures of the native polyamines (putrescine, Put 1, spermidine, Spd 2, and
spermine, Spm 3) and the non-native polyamine (homospermidine, HSpd 4) and MGBG
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Various types of N-alkylpolyamines have been synthesized and shown to provide
promising anticancer activity. The PTS is sensitive to the polyamine structure used; where the
number of nitrogens present and the distance between each plays an integral part.9 However,
while the PTS is sensitive in its molecular recognition of the polyamine chain, it can still
accommodate large N1-substituents.10
Previous work in the Phanstiel lab has shown that the number of methylene spacer units,
the size of the N1 substituent, and the degree of the N1 substitution all influence PTS mediated
delivery.3,9-10 Initially, it was found that an anthryl-homospermidine conjugate 5a had a 150-fold
higher cytotoxicity in CHO cells than in the mutant cell line, CHO-MG, which was PTS
deficient. 3,8b, 9, 11 Utilization of the polyamine transporter was also supported by the ability of
exogenous Spd to outcompete and effectively rescue the cells from the toxicity of the polyamine
based drug.10 It was also observed that the proper polyamine sequence was necessary to
demonstrate PTS selectivity with homospermidine being optimal.10 After demonstrating the high
selectivity of 5a for targeting the PTS, the next question was whether the addition of another
polyamine sequence to the drug platform would enhance the PTS selectivity; in other words
would twice the number of polyamine messages increase the PTS selectivity?12 In order to
answer this question, compounds 6a-8a were synthesized and evaluated in CHO and CHO-MG.
Rewardingly these agents showed a dramatic increase in PTS selectivity (e.g., CHO-MG/CHO
IC50 ratios; 5a: 150, 6a: >2222) .12 Clearly, di-substituted designs dramatically improved
targeting. While this was a definite advance, there were other factors to consider in terms of
optimizing drug design.
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Several factors were shown to affect PTS selectivity and required further structural
optimizations. For example, Polyamine oxidase (PAO) activity severely reduces the PTS
selectivity of polyamine-based drugs via drug degradation. This degradation is inhibited when
aminoguanidine (AG), a known inhibitor of PAO, is added to the growth medium.13 Polyamine
oxidase is known to be present in fetal bovine serum as well as in human blood.14 Specifically,
polyamine oxidase (PAO) is an important enzyme responsible for converting N1-acetylspermine
(54) to spermidine (2) and also for converting N1-acetylspermidine (53) to putrescine (1).14-15
Since polyamine oxidase targets primary amines, it also metabolizes polyamine-based drugs. In
terms of drug design, the primary amine can be protected by N-methylation to avoid the
metabolic and degradative effects of polyamine oxidase activity.16 N-alkylation of the polyamine
termini has many effects on the biological properties of polyamines, including enhanced stability
in the culture medium.11a, 13, 17 In short, polyamine-oxidase-mediated degradation can be
prevented via N-alkylation.11a, 13, 16-17

Figure I-2. Polyamine Biosynthesis
5

For example, compound 5a, which lacks a terminal N-methyl group, showed a profound
loss in PTS selectivity in the absence of AG (CHO-MG/CHO IC50 ratio with AG: 150; without
AG: 4).13 The N-methylated derivative of 5a, compound 5b, was able to retain its PTS selectivity
in the absence of AG (CHO-MG/CHO IC50 ratio of 12.3 with AG, and 11.5 without AG).16
The next step was then to combine the di-substituted design shown to be so effective in
PTS targeting with the N-methylation technology to generate a superior PTS agonist. Therefore,
compounds 6b-8b were generated with the expectation that they would show enhanced
metabolic stability over their non-methylated counterparts (6a-8a) while maintaining high PTS
selectivity in the absence of AG.
The CHO/CHO-MG screen closely resembles the differences between a cancer cell line
and healthy cells. CHO cells can be envisioned as cells with a constitutively active PTS (similar
to many cancer types), while CHO-MG models a healthy normal cell where polyamine transport
activity is minimal.1 A success in this area would be a significant advance because the ability to
target the PTS of cancers could provide new drugs which have lower toxicity in healthy
tissues.17e, 18 Since the polyamine transport system is not fully understood in mammals, these
compounds also represent novel molecular probes to study polyamine transport properties.
Chapter 1 investigates the combination of these two technologies (enhanced targeting via
di-substituted drug designs and N-methylated polyamines) to provide metabolically stable drugs
with excellent PTS targeting.
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Figure I-3. Structures of compounds 5-8
I.3 Results and Discussion
Synthesis. The regional strategy was to generate a modular core platform which could
have the terminal N-alkyl groups introduced in the last step. As shown in Scheme I-1, the
synthesis of 6b-8b began with commercially available 4-amino-1-butanol, 9. By first Boc7

protecting 9 to make 10, the alcohol could be selectively mesylated to give 11. Next, mesylate 11
was reacted with another equivalent of aminoalcohol 9 via nucleophilic substitution to give the
secondary amine 12. The subsequent Boc introduction step sequestered the free 2° nitrogen in 12
as a carbamate through the use of di-tert-butyl dicarbonate to provide Boc protected 13. Both
amines were protected to provide for regiochemical control and provided a more stable
compound amenable to long term storage.3f
Scheme I-1.a Synthesis of 6b (1st Attempt)

a

Reagents: (a) 10%TEA/MeOH, di-tert-butyl dicarbonate; (b) MsCl, TEA/CH2Cl2; (c) 4-amino-

1-butanol, CH3CN; (d) 4 M HCl, EtOH; (e) 25% MeOH/CH2Cl2, anthracene-9,10dicarboxaldehyde; (f) 50% MeOH/CH2Cl2, NaBH4; (g) MsCl, TEA/CH2Cl2; (h) 2.0 M
methylamine in MeOH
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The next stage of the synthesis was initiated by first reacting 13 with 4 M HCl to remove
both Boc protecting groups to generate 14, the HCl salt. Next, 14 was reacted with anthracene9,10-dicarboxaldehyde and NaBH4 via reductive amination to provide diol 15. In this sequence,
the Schiff base was first generated by reacting 14 with the anthracene-9,10-dicarboxaldehyde,
and then NaBH4 reduced the resultant imine intermediate to the corresponding secondary amine,
15. After completion of this step, all four free amines were globally protected again using di-tertbutyl dicarbonate to provide 16. Boc-protected diol 16 was next reacted with methanesulfonyl
chloride to convert both alcohol groups to mesylates, i.e. bismesylate 17. The key step was to
react 17 with methylamine to provide 18. The first attempt at this step was done using 17
dissolved in acetonitrile and adding it to a 2.0 M solution of methylamine in methanol. After
these two reagents were refluxed overnight, the 1H NMR showed a mixture of products. After
performing column chromatography on the crude mixture, 18 could not be isolated in high purity
or high yield (12%). In order to improve upon the yield and purity issues, a new strategy needed
to be developed.
When attempting the reaction of 17 with methylamine again, a new approach was tried.
This attempt did not use acetonitrile, but instead ran the reaction in the methanol provided by the
methylamine solution. The other alteration to this method was to dissolve 17 in a minimal
amount of dichloromethane and add this solution dropwise to a 150-fold excess of a
methylamine/methanol solution over 20 minutes. With these changes in the procedure, 18 was
provided in much higher yield (52%). After seemingly successfully making 18, the final step of
removing the Boc protecting groups was done by again using 4 M HCl, ultimately providing the
final product, 6b. Elemental analysis and 1H NMR, however, showed that both 18 and 6b were
9

not in fact pure, and the purification of 18 proved to be far more difficult than originally thought
as a mixture of the desired product and alcohol byproducts were observed.
After purification of 18 via the synthetic pathway seen in Scheme 1 had failed after
multiple attempts, a new synthetic route was explored. As shown in Scheme 2, the methylated
amine was generated first instead of in the penultimate step. The amino alcohol 9 was reacted
with ethyl formate in ethanol, and the resulting formamide 19 was reduced to 20 using LiAlH4 in
THF.19 This methylated amine was then Boc protected using di-tert-butyl dicarbonate to generate
21 in 84% yield. The production of 21 was confirmed by 1H NMR.20 This protection was
necessary as the next step generated the mesylate 22 using methanesulfonyl chloride. Mesylate
22 was reacted with putrescine in refluxing acetonitrile to afford 23 in 90% yield. This proved to
be very valuable as now the N-methyl polyamine chain was generated prior to reductive
amination to avoid the issues observed in Scheme I-1. Subsequent reductive amination of 23
with anthracene-9,10-dicarboxaldehyde and NaBH4 provided the di-substituted system 24.
However, the tetra-amine was difficult to purify directly due to its multiple amines. Therefore,
24 was globally Boc protected to give 25, which could then in principle be purified by column
chromatography. Unfortunately, the purification of 25 proved to be unsuccessful. The difficulty
ultimately proved to be that when globally Boc protecting 24, some polyamine 23 was also
present which also becomes Boc protected. These two compounds were then seen to have nearly
identical Rf values, and could not be separated from one another.
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Scheme I-2.a Synthesis of 6b (2nd Attempt)

a

Reagents: (a) Ethyl formate, EtOH; (b) LiAlH4, THF; (c) 10% TEA/MeOH, di-tert-butyl

dicarbonate; (d) MsCl, TEA/CH2Cl2; (e) putrescine, K2CO3, CH3CN; (f) 25% MeOH/CH2Cl2,
anthracene-9,10-dicarboxaldehyde; (g) 50% MeOH/CH2Cl2, NaBH4; (h) 4 M HCl, EtOH
After the synthetic routes shown in Schemes I-1 and I-2 failed to afford compound 6b in
high purity, another synthetic route was explored, Scheme I-3. This synthesis began with the
generation of mesylate 22 from alcohol 21 in 95% yield. Mesylate 22 was then reacted with
mono-Cbz-protected putrescine (generated by a known procedure)21 in a nucleophilic
substitution reaction to generate compound 26 in 50% yield. The secondary amine in compound
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26 was then Boc protected to give compound 27 in 99% yield. The Cbz group on compound 28
was then attempted to be removed by hydrogenation conditions (Pd/C), but surprisingly little
conversion was achieved. Although speculative, the proximity of the Boc groups may create a
sterically crowded environment, making it more difficult than initially thought to remove the Cbz
group. A second attempt at hydrogenation was also made through the addition of acetic acid,
which helped in the conversion, but still only allowed for 50% conversion over a one week time
period. While this synthetic route produced the desired polyamine, 28, it did so at the cost of
very low conversion when removing the Cbz group. This prompted a change in the approach to
making compound 28, as it was still the desired target needed for making the final compounds
6b-8b.
Scheme I-3.a Synthesis of 6b (3rd Attempt)

a

Reagents: (a) MsCl, TEA/CH2Cl2; (b) mono-Cbz-putrescine, K2CO3, CH3CN; (c) 10%

TEA/MeOH, di-tert-butyl dicarbonate; (d) Pd/C, AcOH, H2, MeOH; (e) 25% MeOH/CH2Cl2,
anthracene-9,10-dicarboxaldehyde; (f) 50% MeOH/CH2Cl2; (g) 4 M HCl, EtOH
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While multiple synthetic routes had been approached to generate compounds 6b-8b in
high purity, none had proved successful. This led to the development of a procedure to alleviate
the purification issues mentioned for Scheme I-2, and the conversion issues mentioned for
Scheme I-3. As discussed earlier, the desired polyamine for the synthesis of 6b-8b was
compound 28.
In prior work, selectively-protected triamines could be separated from their respective
condensation products with arylaldehydes.3g This method takes advantage of the distinct polarity
differences between primary and secondary amines.22 In order to use this approach, a method
was needed to selectively introduce a Boc group onto a secondary amine in the presence of a
primary amine. Previous work has shown that the chemoselectivity of imine formation with
salicylaldehyde occurs with primary amines exclusively even in the presence of secondary
amines.22 With the primary amine sequestered as an imine, the secondary amine can then be
selectively Boc-protected. Subsequent imine hydrolysis then regenerated the desired primary
amine, 28. Using this approach, polyamine 28 was synthesized with excellent regioselective
control in 47% overall yield from 23.
As shown in Scheme I-4, the synthesis was approached by reacting polyamine 28 with
the appropriate aryl dialdehyde via reductive amination. Fortunately, compounds 29-31 were
successfully generated (55-74% yield) and purified. The methodology developed to generate 28
proved to be invaluable as the purification of 29-31 was straightforward. Finally, with
compounds 29-31 generated, they were treated with 4 M HCl to obtain the respective final
compounds 6b-8b in near quantitative yields.
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Scheme I-4.a Synthesis of 6b (4th Attempt)

a

Reagents: (a) salicylaldehyde, Na2SO4, 25% MeOH/CH2Cl2; (b) di-tert-butyl dicarbonate,

MeOH; (c) 0.1 M HCl, EtOH; (d) aq. Na2CO3, CH2Cl2; (e) aryl-dialdehyde, 25% MeOH/CH2Cl2;
(f) NaBH4, 50% MeOH/CH2Cl2; (g) 4 M HCl, EtOH
Biological Evaluation. Once synthesized, the conjugates were initially screened for
toxicity in CHO, and CHO-MG* cells. CHO cells were chosen along with a mutant PTS
deficient line (CHO-MG*) in order to comment on polyamine transport selectivity.3c-e, 7 The
CHO and CHO-MG* results are shown in Table 1.
The CHO-MG* line was derived from the original CHO-MG line obtained from
Flintoff.8 Due to a freezer failure, the CHO-MG line had to be reisolated from a thermally
compromised lot. This reisolation was successful in providing a mutant line, CHO-MG*, with
the same phenotype (deficient polyamine transport). However, this cell line proved to be slightly
more sensitive to polyamine drugs making the CHO-MG/CHO ratio reduced. For example,
CHO-MG/CHO IC50 ratio for 5a was 150, whereas the CHO-MG*/CHO IC50 ratio for 5a was
43. As the original stocks of CHO-MG were no longer available from their original source,
CHO-MG* were used in the PTS screen.
14

CHO and CHO-MG* Studies. IC50 Determinations. CHO cells were chosen along with
a mutant cell line (CHO-MG*) to comment on how the synthetic conjugates gain access to the
cells. 3c-e, 7 As discussed earlier, the CHO-MG* cell line is polyamine-transport deficient and
represents a model for alternative modes of entry (other than PTS) including passive diffusion or
use of another transporter. The CHO cell line on the other hand, represents cells with high
polyamine transport activity.8b, 11c A comparison of toxicity in these two CHO cell lines provided
a screen that would detect selective use of the polyamine transporter. High utilization of the PTS
by the polyamine compounds would be very toxic to CHO cells. However, reduced toxicity
would be expected in CHO-MG* cells. 3c-e, 7 Ultimately, a CHO-MG*/CHO IC50 ratio was
determined for each compound; where a high ratio would be achieved for highly PTS selective
compounds.
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Table I-1. Biological Evaluation of Polyamine Derivatives (5-8) in CHO and CHO-MG* Cells
in the Presence and Absence of AGa,b,c,d

Compound

5a
(Ant44)
5b
(Ant44NMe)
6a
(44Ant44)
6b
(MeN44Ant44NMe)
7a
(44Nap44)
7b
(MeN44Nap44NMe)
8a
(44Bn44)
8b
(MeN44Bn44NMe)
a

CHOMG* IC50
(µM) w/
AG
13.7
(±1.3)
10.72
(±1.2)
>100
>100
>100
>100
19.6
(±0.8)
51.5
(±2.6)

CHO IC50
(µM) w/
AG

IC50
ratioc w/
AG

0.32
(±0.01)
2.8
(± 0.2)
0.028
(±0.001)
0.083
(±0.004)
0.022
(±0.002)
0.044
(±0.002)
0.027
(±0.001)
0.030
(±0.001)

42.8
3.8
>3571

CHOMG*
IC50
(µM)
w/o AG
2.2
(±0.1)
11.3
(±2.2)
8.4
(±0.7)

>1204

>100

>4545

52.1
(±7.5)

>2272

>100

727
1715

56.5
(±3.5)
54.0
(±2.4)

CHO IC50
(µM) w/o
AG
1.5
(±0.02)
2.1
(±0.06)
4.0
(±0.3)
0.084
(±0.002)
5.5 (±0.5)
0.039
(±0.001)
10.3
(±0.9)
0.041
(±0.002)

IC50
ratioc
w/o AG
1.4
5.4
2.1
>1190
9.5
>2564
5.5
1316

Cells were incubated for 48 h at 37°C with the respective conjugate. b1 mM AG was incubated

with cells for 24 h prior to drug addition cThe ratio denotes the (CHO-MG*/CHO) IC50 ratio, a
measure of PTS selectivity dAll experiments were done in triplicate.
As reported earlier,3g dramatic differences in CHO and CHO-MG* cytotoxicity (Table I1) were observed for 5a, however, the difference was not as great as the original CHO-MG line
used (e.g., CHO-MG/CHO IC50 ratio of 5a: 148, CHO-MG*/CHO IC50 ratio of 5a: 43). This
slightly modified CHO-MG* cell line still showed less sensitivity to the polyamine conjugate
drugs than CHO, however, not to the extent as the original cell line, CHO-MG. This led to the
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determination of the IC50 values of all drugs previously tested in this modified CHO-MG* cell
line to facilitate comparisons.
This new CHO screen again showed a dramatic increase in PTS selectivity when a
second polyamine message was attached to the cytotoxic (aryl) core (e.g. CHO-MG*/CHO IC50
ratio of 6a: >3571, CHO-MG*/CHO IC50 ratio of 5a: 43). This was expected as an increase in
the number of appended polyamine messages should increase the drug conjugates’ ability to gain
entry via the PTS. As observed earlier12, however, adding a third polyamine message did not
further increase in PTS selectivity, but instead showed a tremendous decrease in PTS selectivity
for compound 32 ( CHO-MG*/CHO IC50 ratio of 1). While compound 32 was found to be an
inferior PTS ligand, it would be found to be an excellent PTS inhibitor, which will be discussed
later in Chapter 2.

Figure I-4. Structure of 32 (Trimer44)
Despite these unprecedented PTS selectivities that were found for the di-substituted
polyamine conjugates, they were found to have one distinct limitation. This limitation was found
to be their sensitivity to serum amine oxidase. Aminoguanidine13 (AG) is a known inhibitor of
serum amine oxidases and is routinely added (1 mM) during the cell culture experiments to avoid
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polyamine drug degradation by the serum oxidase. Experiments performed in the absence of AG
showed a severe decrease in PTS selectivity (e.g. CHO-MG*/CHO IC50 ratio with AG of 6a:
>3571, CHO-MG*/CHO IC50 ratio without AG of 6a: 2.1). However, N-methyl derivative 5b
showed that metabolic stability could be achieved via N-methylation, (CHO-MG*/CHO IC50
ratio with AG=3.8, CHO-MG*/CHO IC50 ratio without AG=5.4).
By design, compounds 6b-8b combined the best features of the di-substituted platforms
with the N-methylation strategy. Rewardingly, compounds 6b-8b retained their high selectivity
in targeting the PTS with and without the AG additive. For example, each of the N-methylated
derivatives (5b, 6b, 7b, and 8b) in Table I-1 retained their PTS targeting property even in the
absence of AG. Compounds 6b-8b proved that a polyamine based drug conjugate could be
designed to be metabolically stable while at the same time being highly PTS selective.
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Figure I-5. NCI 60 cell-line screen of 6a (44Ant44)a
a

High cytotoxicity was observed in compounds with bars extending to the right
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Figure I-6. NCI 60 cell-line screen of 6b (MeN44Ant44NMe)a
a

High cytotoxicity was observed in compounds with bars extending to the right
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MALME-3 and MALME-3M Studies. IC50 Determinations. Once compounds 6a and
6b were evaluated in CHO and CHO-MG*, these compounds were sent to NCI to conduct its 60
cell-line screen to determine if these compounds could also be potent anti-cancer agents for
human cancer cell lines. Due to the robotic aspects of the NCI screen, AG was not added during
their screens of 6a and 6b. This screen showed that 6a was toxic to a wide range of different
cancer cells and thus was chosen to advance to the hollow fiber tube assay. While this finding
was interesting in its own right, it likely is an artifact of drug degradation. An even more
interesting finding was the incredible selectivity 6b seemed to possess for the MALME-3M cell
line. While 6b inhibited growth for some of the cell lines, it was only the MALME-3M cell line
where it was seen to both inhibit growth and kill cells.
The sensitivity of the MALME-3M cell line to 6b was reconfirmed by NCI through a 5dose assay where a dose dependent response was observed. Armed with this insight, the
MALME-3M (melanoma) cell line and its non-cancerous counterpart MALME-3 were
purchased from ATCC. These matched cell lines provided a method to assess PTS selectivity for
the cancer line (MALME-3M) over the non-cancerous cell line (MALME-3). These results
obtained for 5-8 are shown in Table I-2.
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Table I-2. Biological Evaluation of Polyamine Derivatives (5-8) in MALME-3 and MALME3M Cells in the Presence of AGa,b,c,d
Compound
5a
(Ant44)
5b
(Ant44NMe)
6a
(44Ant44)
6b
(MeN44Ant44NMe)
7a
(44Nap44)
7b
(MeN44Nap44NMe)
8a
(44Bn44)
8b
(MeN44Bn44NMe)
a

MALME-3 IC50 (µM)

MALME-3M IC50 (µM)

IC50 ratioc

0.83 (±0.03)

0.27 (±0.01)

3.1

0.62 (±0.01)

0.45 (±0.01)

1.4

0.69 (±0.02)

0.017 (±0.001)

41

1.00 (±0.01)

0.062 (±0.002)

16

1.27 (±0.09)

0.018 (±0.001)

71

0.82 (±0.06)

0.014 (±0.001)

59

0.09 (±0.01)

0.005 (±0.0002)

18

0.02 (±0.001)

0.01 (±0.0001)

2

Cells were incubated for 96 h at 37°C with the respective conjugate. b1 mM AG was determined

to be non-toxic and incubated with MALME-3M and MALME-3 cells for 24 h prior to drug
addition. This facilitated comparisons between the drugs tested. cThe ratio denotes the
(MALME-3/MALME-3M) IC50 ratio, a measure of selectivity dAll experiments were done in
triplicate using RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin.
When compounds 5-8 were tested in MALME-3M and MALME-3, it was discovered
that a 96 h viability assay was necessary due to the slow growth rates of MALME-3M (doubling
time=48 h) and MALME-3 (doubling time=96 h) when using the media described for Table I-2.
With this assay in place, compounds 5-8 all showed high cytotoxicity (IC50<500 nM) in
MALME-3M, with the di-substituted platforms (6-8) proving to be the most potent as seen in
Table I-2. It was also seen, with the exception of compound 7b, that the non-methylated
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derivatives (5a, 6a, and 8a) all showed enhanced toxicity over their methylated counterparts in
the presence of AG. The aryl core of each compound also demonstrated a significant effect as the
benzylic compounds (8a and 8b) proved to be the most toxic, while the toxicities for the anthryl
and naphthyl derivatives were very similar. As expected, the mono-substituted compounds 5a
and 5b were significantly less toxic in MALME-3M and exhibited low selectivity for the
MALME-3M cell line.
Despite the enhanced toxicity of 8a and 8b in MALME-3M, they demonstrated the
poorest selectivity for the MALME-3M cell line over the MALME-3 cell line in the disubstituted series. This result is consistent with findings observed in CHO/CHO-MG*, where the
benzylic derivatives (8a and 8b) also exhibited the lowest PTS selectivity. This enhanced
toxicity, yet modest of selectivity could be attributed to the benzylic core being more prone to
metabolism, and being degraded into toxic metabolites. Prior work showed that the monosubstituted benzyl-homospermidine motif was converted to free homospermidine, whereas the
naphthyl and anthryl derivatives were dramatically less prone to degradation.
In the present studies, the anthryl and naphthyl cores (6-7) demonstrated increased
selectivity for MALME-3M over MALME-3. A surprising find, however, was that 6b showed a
significantly lower selectivity than its non-methylated anthryl derivative, 6a, and also lower than
its naphthyl derivative, 7b. This finding for compounds 6a, 7a, and 7b was very interesting, and
could be attributed to enhanced uptake of polyamines through the PTS of cancer cells (i.e.
MALME-3M) when compared to the lower level of uptake for non-cancerous cells (i.e.
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MALME-3). The hypothesis that these toxicities were attributed to uptake through the PTS was
tested in a series of spermidine (Spd) rescue experiments shown in Figures I-6 through I-11.
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Figure I-7. Ability of Spd to rescue MALME-3M and MALME-3 cells treated with compound
6a (44Ant44)a,b,c,d
a

Cells were incubated for 96 h at 37°C with compound 6a at 0.02 µM (MALME-3M) and 0.6

µM (MALME-3). b1 mM AG was determined to be non-toxic and was incubated with cells for
24 h prior to drug addition. cControl is no drug control. dAll experiments were done in triplicate
using RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin.
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Figure I-8. Ability of Spd to rescue MALME-3M and MALME-3 cells treated with compound
6b (MeN44Ant44NMe)a,b,c,d
a

Cells were incubated for 96 h at 37°C with compound 6b at 0.06 µM (MALME-3M) and 1 µM

(MALME-3). b1 mM AG was determined to be non-toxic and was incubated with cells for 24 h
prior to drug addition. cControl is no drug control. dAll experiments were done in triplicate using
RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin.
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Figure I-9. Ability of Spd to rescue MALME-3M and MALME-3 cells treated with compound
7a (44Nap44)a,b,c,d
a

Cells were incubated for 96 h at 37°C with compound 7a at 0.02 µM (MALME-3M) and 1 µM

(MALME-3). b1 mM AG was determined to be non-toxic and was incubated with cells for 24 h
prior to drug addition. cControl is no drug control. dAll experiments were done in triplicate using
RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin.
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Figure I-10. Ability of Spd to rescue MALME-3M and MALME-3 cells treated with compound
7b (MeN44Nap44NMe)a,b,c,d
a

Cells were incubated for 96 h at 37°C with compound 7b at 0.02 µM (MALME-3M) and 0.8

µM (MALME-3). b1 mM AG was determined to be non-toxic and was incubated with cells for
24 h prior to drug addition. cControl is no drug control. dAll experiments were done in triplicate
using RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin.

27

160
140

% Viability

120
100
80

MALME-3M

60

MALME-3

40
20
0
control
Control

8a only
only
8a

+ 0.1
8a ++ 100
100
8a8a
+ 0.1
µM 8a8a+ +1 1µM 8a8a+ +1010µM 8a
µM
Spd
µM
Spd
µM
Spd
µM
Spd
Spd
Spd
µM Spd
Spd

Figure I-11. Ability of Spd to rescue MALME-3M and MALME-3 cells treated with 8a
(44Bn44)a,b,c,d
a

Cells were incubated for 96 h at 37°C with compound 8a at 0.01 µM (MALME-3M) and 0.1

µM (MALME-3). b1 mM AG was determined to be non-toxic and was incubated with cells for
24 h prior to drug addition. cControl is no drug control. dAll experiments were done in triplicate
using RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin.
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Figure I-12. Ability of Spd to rescue MALME-3M and MALME-3 cells treated with 8b
(MeN44Bn44NMe) a,b,c,d
a

Cells were incubated for 96 h at 37°C with compound 8b at 0.01 µM (MALME-3M) and 0.02

µM (MALME-3). b1 mM AG was determined to be non-toxic and was incubated with cells for
24 h prior to drug addition. cControl is no drug control. dAll experiments were done in triplicate
using RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin.
Spd Rescue Experiments. As stated above, in an effort to determine if the cytotoxicities
seen for compounds 6-8 were polyamine transport related, MALME-3M and MALME-3 were
dosed near the IC50 value of each drug. These cells were also treated with increasing amounts of
Spd to see if it could outcompete compounds 6-8 for cellular entry and thus rescue the cells.
Compounds 6-7 each showed that exogenous Spd was able to significantly rescue (~90%
viability) MALME-3M and MALME-3 cells from the cytotoxicity of these compounds. This
supports the premise that these compounds gain access to these cells primarily via the PTS.
When exogenous Spd was added to 8a and 8b (Figures I-10 and I-11 respectively), a much lower
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level of rescue was observed in MALME-3M (<80% viability). However, complete rescue was
observed in MALME-3. Since the viability of MALME-3M cells could be partially rescued by
Spd, compounds 8a and 8b may gain access via the PTS, along with non-PTS related
pathway(s). These results correlate well with the finding that 6 and 7 (anthryl and naphthyl cores
respectively) prefer MALME-3M and its upregulated PTS over MALME-3. In contrast, 8a and
8b did not demonstrate the same degree of selectivity.
It is also interesting to note that while Spd was able to rescue both MALME-3M and
MALME-3 from the toxic effects of 6-8, a large excess of Spd was necessary. As seen in Figures
I-7 through I-12, between 10 and 100 µM Spd was needed to get significant rescue. Since
compounds 6-8 exhibited ~50% viability at very low doses (0.01 µM to 0.06 µM for MALME3M, and 0.02 µM to 1 µM for MALME-3), a very large molar excess of Spd was necessary to
outcompete these compounds. These results can be partially attributed to significant differences
in Ki values (lower Ki=better binding affinity) observed in L1210 cells for compounds 6a
(Ki=0.39 µM), 7a (Ki=0.17 µM), and 8a (Ki=0.52 µM) as compared to Spd (Ki=2.46 µM).3d, 12
These findings suggest that these di-substituted compounds have a much higher affinity for the
PTS as compared to Spd, thus requiring a large molar excess of Spd to outcompete 6-8 for the
PTS.
The Spd rescue results coupled with the high sensitivity of MALME-3M to compounds
5-8, leads to three different hypotheses. One hypothesis is that these compounds are toxic
primarily due to their ability to exploit the upregulated PTS of cancer cells, allowing them to
deliver their toxic cargo. The other hypothesis is that these alkylated polyamines led to an
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increase in SSAT activity, which in turn caused an increase in native polyamine metabolism,
followed by an increase in export, which ultimately leads to cell death. This second hypothesis is
predicated on work done by Porter et.al., who showed that when MALME-3M was treated with
alkylated polyamines, a dramatic increase in SSAT activity was observed, leading to decreased
levels of native polyamine pools.9, 11a, b, 17b, 17d, 23 The third hypothesis is that a combination effect
of decreased levels of native polyamines and increased levels of the drug causes the MALME3M cells to be more sensitive to cell death, thus allowing the cytotoxic cargo to have a more
profound effect. Future studies are needed to address these remaining questions.
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Table I-3. Biological Evaluation of Polyamine Derivatives (5-8) in MALME-3M Cells in the
Presence and Absence of AGa,b,c
Compound
5a
(Ant44)
5b
(Ant44NMe)
6a
(44Ant44)
6b
(MeN44Ant44NMe)
7a
(44Nap44)
7b
(MeN44Nap44NMe)
8a
(44Bn44)
8b
(MeN44Bn44NMe)
a

MALME-3M IC50 (µM) w/ AG

MALME-3M IC50 (µM) w/o AG

0.48 (±0.03)

0.29 (±0.03)

0.60 (±0.06)

0.62 (±0.06)

0.088 (±0.004)

0.29 (±0.005)

0.125 (±0.004)

0.16 (±0.02)

0.043 (±0.001)

0.43 (±0.06)

0.104 (±0.002)

0.168 (±0.006)

0.0102 (±0.0002)

0.4 (±0.02)

0.007 (±0.0001)

0.007 (±0.0004)

Cells were incubated for 48 h at 37°C with the respective conjugate. b1 mM AG was determined

to be non-toxic and incubated with MALME-3M cells for 24 h prior to drug addition. cAll
experiments were done in triplicate using RPMI 1640 supplemented with 10% Nu-Serum IV and
1% penicillin/streptomycin.
IC50 Determinations in the Presence and Absence of AG. Prior to the IC50 determinations
for MALME-3M and MALME-3 in a 96 h assay, IC50 values were determined for MALME-3M
in a 48 h assay using 10% Nu-Serum IV. In order to verify the enhanced metabolic stability of
methylated compounds 5b, 6b, 7b, and 8b over their non-methylated counter parts (5a, 6a, 7a,
and 8a) in MALME-3M, their IC50 values were determined with and without AG. While the
mono-substituted compounds 5a and 5b showed little to no difference in IC50 values in the
absence of AG, a dramatic change was seen for the di-substituted compounds (6-8). While the
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methylated compounds demonstrated the same IC50 values in the presence and absence of AG, a
profound increase in IC50 value (4 to 70 fold) was observed for the non-methylated derivatives in
the absence of AG. This trend was also observed in CHO (Table I-1), where an absence of AG
led to increased IC50 values for the non-methylated derivatives and not the methylated
derivatives. This finding suggests that in future in vivo studies compounds 6b, 7b and 8b could
be dosed without the addition of AG.
I.4 Summary
Studies in CHO and CHO-MG* illustrated that a combination of a di-substituted platform
coupled with terminal N-methylation of the appended polyamine chains is a hyperselective PTS
design with improved metabolic stability. These results have also demonstrated that the aryl core
plays a key role with the anthryl or naphthyl cores being the most PTS selective design. These
trends were also observed in the MALME-3M/MALME-3 screen, where enhanced metabolic
stability was observed, and the anthryl and naphthyl systems gave the best selectivity. The ability
to significantly rescue MALME-3M cells with Spd for compounds 6a, 6b, 7a, and 7b further
points to their utilization of the PTS and demonstrates the PTS-mediated cell-selective drug
delivery in a human melanoma line, MALME-3M over its normal counterpart MALME-3.
I.5 Experimental
I.5.1 Materials.
Silica gel (32-63 µm) and chemical reagents were purchased from commercial sources
and used without further purification. All solvents were distilled prior to use. All reactions were
carried out under an N2 atmosphere. 1H and 13C spectra were recorded at 400 or 75 MHz,
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respectively. TLC solvent systems were listed as volume percents, and NH4OH referred to
concentrated aqueous NH4OH. All tested compounds provided satisfactory elemental analyses.
I.5.2 Biological Studies.
CHO and CHO-MG* cells were grown in RPMI 1640 medium supplemented with 10%
fetal calf serum and 1% penicillin/streptomycin. Note: the media must contain L-proline
(2µg/mL) for proper growth of the CHO-MG* cells. MALME-3M and MALME-3 cells were
grown in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin for
96 h experiments, and RPMI 1640 medium supplemented with 10% Nu-Serum IV and 1%
penicillin/streptomycin for 96 h experiments. All cells were grown at 37°C under a humidified
5% CO2 atmosphere. Aminoguanidine (1 mM) was added to the growth medium to prevent
oxidation of the drugs by the enzyme (bovine serum amine oxidase) present in calf serum. Cells
in early to mid-log phase were used.
IC50 Determinations. Cell growth was assayed in sterile 96-well microtiter plates
(Costar 3599, Corning, NY, USA). CHO and CHO-MG* cells were plated at 10,000 cells/mL.
MALME-3M and MALME-3 cells were plated at 5,000 cells/mL. Drug solutions (10 µL per
well) of appropriate concentration were added after an overnight incubation for each CHO cell
line (90 µL). 48 h MALME-3M experiments were conducted using 10% Nu-Serum IV, and 96 h
MALME-3M and MALME-3 experiments were conducted using 10% FBS. After exposure to
the drug for 48 h (CHO, CHO-MG*, and MALME-3M) or 96 h (MALME-3M and MALME-3),
cell growth was determined by measuring formazan formation from 3-(4,5-dimethylthiazol-2-
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yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-tetrazolium, inner salt (MTS) using a
SynergyMx Biotek microplate reader for absorbance (490 nM) measurements.24
I.5.3 Synthetic Procedures and Characterization
N1,N1'-(Anthracene-9,10-diylbis(methylene))bis(N4-(4-(methylamino)butyl)butane1,4-diamine), 6b. Orange solid (93%); 1H NMR (D2O) δ 8.33 (dd, 4H), 7.82 (dd, 4H), 5.18 (s,
4H), 3.38 (t, 4H), 3.16 (12H), 2.76 (s, 6H), 1.84 (m, 16H); 13C NMR (D2O) δ 185.5, 129.9,
127.7, 125.1, 124.0, 48.2, 47.5, 46.9, 46.8, 42.9, 32.7, 22.9, 22.8, 22.7, 22.6. HRMS (FAB) m/z
calc for C34H56N6 (M + H)+ 549.4566; found 549.4639. Elemental Analysis: C34H62N6Cl6•1.25
H2O theory C: 51.69, H: 8.23, N: 10.64; found C: 51.66, H: 8.05, N: 10.49.
N1,N1'-(Naphthalene-1,4-diylbis(methylene))bis(N4-(4-(methylamino)butyl)butane1,4-diamine), 7b. Yellow solid (98%); 1H NMR (D2O) δ 8.25 (dd, 2 H), 7.83 (dd, 2H), 7.75 (s,
2H), 4.85 (s, 4H), 3.34 (t, 4H), 3.15 (t, 12H), 2.75 (s, 3H), 1.83 (m, 16H); 13C NMR (D2O) δ
134.3, 132.2, 131.5, 130.9, 126.8, 51.2, 51.0, 50.2, 49.9, 35.7, 25.9, 25.8, 25.6. HRMS (FAB)
m/z calc for C30H54N6 (M + H)+ 499.4410; found 499.4479. Elemental Analysis: C30H60N6Cl6•2
H2O theory C: 47.82, H: 8.56, N: 11.15; found C: 47.85, H: 8.35, N: 10.82.
N1,N1'-(1,4-Phenylenebis(methylene))bis(N4-(4-(methylamino)butyl)butane-1,4diamine), 8b. While solid (99%); 1H NMR (D2O) δ 7.61 (s, 4H), 4.28 (s, 4H), 3.21-3.12 (t,
16H), 1.78 (m, 16H); 13C NMR (D2O) δ 135.0, 133.4, 53.5, 51.1, 49.7, 49.4, 35.6, 25.7, 25.6,
25.5. HRMS (FAB) m/z calc for C26H52N6 (M + H)+ 449.4253; found 449.4326. Elemental
Analysis: C26H58N6Cl6 theory C: 46.79, H: 8.76, N: 12.59; found C: 46.69, H: 8.82, N: 12.33.
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(4-hydroxybutyl)carbamic acid tert-butyl ester, 10.3f A solution of 4-amino-1-butanol
9 (5 g, 56.1 mmol) in TEA/MeOH (1:7 v/v, 150 mL) was stirred at 0°C for 10 min. A solution of
di-tert-butyl dicarbonate (18.4 g, 84.1 mmol) in MeOH (40 mL) was added dropwise over 10
min. The mixture was stirred for 1 h under N2 atmosphere. The temperature was allowed to
gradually rise to room temperature, and the solution was then stirred overnight. The solution was
evaporated under reduced pressure, and the residue was dissolved in CH2Cl2 and washed three
times with deionized water. The organic layer was separated, dried over anhydrous Na2SO4,
filtered, and concentrated to give 10 as a colorless oil 10 (9.78 g, 92%) that was used in the next
step without further purification. Rf=0.4 (40% acetone/hexane); 1H NMR (CDCl3) δ 4.96 (br s,
1H, NH), 3.62 (m, 2H, OCH2), 3.11 (m, 2H, NCH2), 2.49 (m, 1H, OH), 1.55 (m, 4H, CH2), 1.41
(s, 9H, CH3). Matched literature values.25
Methanesulfonic Acid 4-tert-Butoxycarbonylaminobutyl Ester, 11.25 To a solution of
the alcohol 10 (9.78 g, 51.4 mmol) and TEA (35.8 mL, 257 mmol) in CH2Cl2 (130 mL) at 0°C,
methanesulfonyl chloride (29.5 g, 257 mmol) was added dropwise over 30 min under a N2
atmosphere. The reaction mixture was stirred at 0°C for 1 h and was slowly warmed to room
temperature and stirred overnight under N2. The reaction mixture was then cooled to 0°C, and a 4
M NaOH solution (50 mL) was added slowly with vigorous stirring. The organic phase was
separated and washed with water (2 x 70 mL). The organic phase was separated, dried over
anhydrous Na2SO4, filtered and concentrated to give the product 11 (12.7 g, 92%) as a clear oil
that was used in the next step without further purification. Rf=0.5 (40% acetone/hexane); 1H
NMR (CDCl3) δ 4.85 (br s, 1H, NH), 4.27 (t, 2H, OCH2), 3.16 (m, 2H, NCH2), 3.01 (s, 3H,
CH3), 1.78 (quin, 2H, CH2), 1.59 (quin, 2H, CH2), 1.43 (s, 9H, CH3). Matched literature values.25
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[4-(4-Hydroxybutylamino) butyl] carbamic Acid tert-Butyl Ester, 12.25 The mesylate
11 (12.65 g, 47.2 mmol) and 4-amino-1-butanol (12.62 g, 142 mmol) were dissolved in
acetonitrile (30 mL). The mixture was then stirred at 75°C reflux under a N2 atmosphere
overnight. After the confirmation of the disappearance of the mesylate by TLC, the solution was
concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (30 mL) and washed
three times with aqueous sodium carbonate. The organic layer was separated, dried with
anhydrous Na2SO4, filtered, and concentrated under vacuum to give 12 as a yellow oil (10.3 g;
84%). Rf=0.33 (1:7:92, NH4OH/MeOH/CH2Cl2; 1H NMR (CDCl3) δ 5.05 (br s, 1H, NHCO),
3.54 (t, 2H, OCH2), 3.07 (m, 2H, BocNCH2), 2.61 (m, 4H, NCH2), 1.64 (quin, 4H, CH2), 1.55
(quin, 4H, CH2), 1.42 (s, 9H, CH3). Matched literature values.25
(4-tert-Butoxycarbonylaminobutyl)-(4-hydroxybutyl)-carbamic Acid tert-Butyl
Ester, 13.25 A solution of 12 (10.3 g, 39.6 mmol) in triethylamine/MeOH (1:7 v/v, 160 mL) was
stirred at 0°C for 10 min. A solution of di-tert-butyl dicarbonate (13.0 g, 56.4 mmol) in MeOH
(40 mL) was added dropwise over 10 min. The mixture was stirred for 1 h at 0°C. The
temperature was then allowed to gradually rise to room temperature, and the solution was stirred
overnight under a N2 atmosphere. The solution was then evaporated under reduced pressure, and
the residue was dissolved in CH2Cl2 and washed with deionized water several times. The organic
layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated to give 13 as an oil.
Column chromatography gave 13 as a colorless oil, (8.75 g, 53% over two steps). Rf=0.35
(0.5:3:96.5 NH4OH/MeOH/CH2Cl2); 1H NMR (CDCl3) δ 7.24 (br s, 1H, NH), 3.62 (t, 2H,
OCH2), 3.20 (t, 6H, NCH2), 2.0 (br s, 1H, OH), 1.6 (m, 8H, CH2), 1.42 (s, 18H, CH3). Matched
literature values.25
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4-(4-Amino-butylamino)-butan-1-ol, 14. A solution of Boc-protected 13 (630 mg, 1.75
mmol) was dissolved in absolute ethanol (20 mL) and stirred at 0°C for 10 min. A 4 N HCl
solution (35 mL, 140 mmol) was added to the reaction mixture dropwise and stirred at 0°C for
30 min and then at room temperature overnight. The solution was concentrated in vacuo to give
14 as a white solid, (400 mg; 98% yield); 1H NMR (D2O) δ 3.62 (t, 2H, NCH2), 3.18 (m, 6H,
CH2), 1.75 (m, 6H, CH2), 1.65 (m, 1H, CH2).
4-{4-[(10-{[4-(4-Hydroxy-butylamino)-butylamino]-methyl}-anthracen-9-ylmethyl)amino]-butylamino}-butan-1-ol, 15. To a stirred solution of 14 (370 mg, 1.6 mmol) in 25%
MeOH/CH2Cl2 (20 mL) and TEA (0.57 mL, 4.0 mmol) was added 9,10anthracenedicarboxaldehyde (170 mg, 0.72 mmol) under N2. The mixture was stirred at room
temperature overnight until the imine formation was complete (by 1H NMR). The solvent was
removed in vacuo, and the solid residue was dissolved in 50% MeOH/CH2Cl2 (20 mL), and the
solution was cooled to 0°C. NaBH4 (164 mg, 4.3 mmol) was added in small portions to the
solution, and the mixture was stirred at room temperature overnight. The solvent was removed in
vacuo, and the solid residue was dissolved in CH2Cl2 (50 mL) and washed with 10% aqueous
Na2CO3 solution (3 x 30 mL). The CH2Cl2 layer was dried over anhydrous Na2SO4, filtered,
concentrated to give an oily residue. The oil was purified by flash column chromatography to
yield 15 as a pale-yellow oil; (310 mg, 83%) Rf=0.25 (3:20:77 NH4OH/MeOH/CH2Cl2; 1H NMR
(CDCl3) δ 8.39 (dd, 4H, CH), 7.45 (dd, 4H, CH), 4.65 (s, 4H, CH2), 4.48 (t, 4H, CH2), 2.90 (m,
8H, CH2), 1.60 (m, 16 H, CH2); 13C NMR (CDCl3) δ 132.2, 130.2, 125.8, 125.0, 62.6, 50.5, 49.7,
49.5, 32.7, 28.9, 28.0, 27.7. HRMS (FAB) m/z calc for C32H50N4O2 (H + M)+ 522.3934, found
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523.4007. Elemental Analysis: C32H50N4O2·1 H2O theory C: 71.1, H: 9.70, N: 10.36; found C:
71.55, H: 9.62, N: 10.29.
{10-[(tert-Butoxycarbonyl-{4-[tert-butoxycarbonyl-(4-hydroxy-butyl)-amino]butyl}-amino)-methyl]-anthracen-9-ylmethyl}-{4-[tert-butoxycarbonyl-(4-hydroxy-butyl)amino]-butyl}-carbamic acid tert-butyl ester, 16. A solution of 15 (310 mg, 0.60 mmol) in
triethylamine/MeOH (1:7 v/v, 80 mL) was stirred at 0°C for 10 min. A solution of di-tert-butyl
dicarbonate (651 mg, 3.0 mmol) in MeOH (20 mL) was added dropwise over 10 min. The
mixture was stirred for 1 h under a N2 atmosphere. The temperature was allowed to gradually
rise to room temperature, and the solution was stirred overnight. The solution was evaporated
under reduced pressure, and the residue was dissolved in CH2Cl2 and washed with deionized
water. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated
to give 16 as a colorless oil (501 mg, 91% yield) which was used in the next step without further
purification; 1H NMR (CDCl3) δ 8.45 (dd, 4H, CH), 7.59 (dd, 4H, CH), 5.59 (s, 4H, CH2), 3.60
(s, 4H, CH2), 2.8 (d, 12H, CH2), 1.4 (m, 36H, CH3); 13C NMR (CDCl3) δ 155.9, 131.2, 130.0,
125.9, 125.1, 79.8, 79.5, 61.9, 46.5, 44.2, 41.5, 29.8, 28.3, 25.9, 25.8, 25.5, 24.6. HRMS (FAB)
m/z calc for C52H82N4O10 (H + M)+ 922.6031, found 922.6104. Elemental Analysis:
C52H82N4O10·1 H2O theory C: 66.36, H: 9.00, N: 5.95; found C: 66.33, H: 9.01, N: 5.83.
Methanesulfonic acid 4-{tert-butoxycarbonyl-[4-(tert-butoxycarbonyl-{10-[(tertbutoxycarbonyl-{4-[tert-butoxycarbonyl-(4-methanesulfonyloxy-butyl)-amino]-butyl}amino)-methyl]-anthracen-9-ylmethyl}-amino)-butyl]-amino}-butyl ester, 17. To a solution
of the alcohol 16 (485 mg, 0.53 mmol) and triethylamine (0.6 mL, 4.2 mmol) in CH2Cl2 (20 mL)
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at 0°C, methanesulfonyl chloride (483 mg, 4.2 mmol) was added dropwise over 30 min under a
N2 atmosphere. The reaction mixture was stirred at 0°C for 1 h and was slowly warmed to room
temperature and stirred overnight under N2. The reaction mixture was then cooled to 0°C, and a 1
M NaOH solution (20 mL) was added slowly with vigorous stirring. The organic phase was
separated and washed with water (2x15 mL). The organic phase was separated, dried over
anhydrous Na2SO4, filtered and concentrated to give the product 17 as a colorless oil (500 mg,
88%) which was used in the next step without further purification, Rf=0.24 (2:98
MeOH/CH2Cl2); 1H NMR (CDCl3) δ 8.45 (dd, 4H, CH), 7.60 (dd, 4H, CH), 5.58 (s, 4H, CH2),
4.23 (s, 6H, CH3), 3.10 (d, 12 H, CH2), 1.45 (m, 36 H, CH3).
[4-(tert-Butoxycarbonyl-{10-[(tert-butoxycarbonyl-{4-[tert-butoxycarbonyl-(4methylamino-butyl)-amino]-butyl}-amino)-methyl]-anthracen-9-ylmethyl}-amino)-butyl](4-methylamino-butyl)-carbamic acid tert-butyl ester, 18. A solution of 2.0 M methylamine
in MeOH (6 mL, 12 mmol) and K2CO3 was brought to reflux while stirring. A solution of 17 (80
mg, 0.074 mmol) in CH2Cl2 (5 mL) was added dropwise over 15 min, and the reaction was
stirred overnight at reflux under N2. The K2CO3 was filtered off and the filtrate was concentrated
under vacuum, and redissolved in CH2Cl2 (50 mL) to precipitate unwanted inorganics, filtered
again and concentrated, to give a crude residue. Column chromatography (1:11:88
NH4OH/MeOH/CH2Cl2) yielded 37 mg of 18 (53%), 1H NMR (CDCl3) δ 8.42 (dd, 4H, CH),
7.59 (dd, 4H, CH), 5.59 (s, 4H, CH2), 2.80 (m, 12 H, CH2), 2.42 (s, 3H, CH3), 1.45 (m, 36H,
CH3). Failed elemental analysis
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N-(4-hydroxybutyl)formamide (19). To a stirred solution of 9 (4.31 g, 48.4 mmol) in
EtOH (50 mL) was added ethylformate (5.86 mL, 75.5 mmol) and the mixture was stirred at
reflux for 18 hrs under N2. The solution was evaporated under reduced pressure, and the crude
product, 19, was used in the next step without further purification (4.8 g crude mass). 1H NMR
(CDCl3) δ 8.02 (s, 1H), 3.57 (t, 2H), 3.24 (t, 2H), 1.56 (m, 4H).
4-Methylamino-butan-1-ol, 20.19 The crude reaction mixture was dissolved in THF (25
mL) and added to a suspension of LiAlH4 (5.50 g, 145 mmol) in THF (50 mL) dropwise under a
drying tube while stirring. The reaction mixture was brought to reflux and monitored by TLC
(20% EtOH/80% CHCl3) and 1H NMR (CDCl3). After 2 hours, the starting material was
consumed, and H2O (4.16 mL) was added to the cooled reaction mixture, followed by 4 M
NaOH (4.16 mL) and H2O (12.5 mL) while stirring vigorously. The precipitate was then
removed by filtration, and the filtrate concentrated in vacuo. The residue was redissolved in
CHCl3, dried over Na2SO4, filtered and concentrated under reduced pressure to give 20 as a
colorless oil (2.76 g, 56%); 1H NMR (CDCl3) δ 3.74 (br, 2H), 3.57 (t, 2H), 2.62 (t, 2H), 2.43 (s,
3H), 1.50-1.75 (m, 4H). Matched literature values.19
(4-Hydroxy-butyl)-methyl-carbamic acid tert-butyl ester, 21.20 A solution of 20 (2.76
g, 26.8 mmol) in TEA/MeOH (1:7 v/v, 100 mL) was stirred at 0°C for 10 min. A solution of ditert-butyl dicarbonate (8.76 g, 40.2 mmol) in MeOH (20 mL) was added dropwise over 10 min.
The mixture was stirred for 1 h under N2 atmosphere. The temperature was allowed to gradually
rise to room temperature, and the solution was stirred overnight. The solution was evaporated
under reduced pressure, and the residue was dissolved in CH2Cl2 and washed with deionized
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water. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated
to give a colorless oil 21 that was used in the next step without further purification (4.54 g, 84%);
1

H NMR (CDCl3) δ 3.66 (t, 2H), 3.23 (t, 2H), 2.83 (s, 3H), 1.78 (br s, 1H), 1.51-1.60 (m, 4H),

1.44 (s, 9H). Matched literature values.20
Methanesulfonic acid 4-(tert-butoxycarbonyl-methyl-amino)-butyl ester, 22. To a
solution of the alcohol 21 (4.54 g, 22.24 mmol) and TEA (15.5 mL, 111 mmol) in CH2Cl2 (60
mL) at 0°C, methanesulfonyl chloride (12.73 g, 111 mmol) was added dropwise over 30 min
under a N2 atmosphere. The reaction mixture was stirred at 0°C for 1 hr and was slowly warmed
to room temperature and stirred overnight under N2. The reaction mixture was then cooled to
0°C, and a 1 M NaOH solution (500 mL) was added slowly with vigorous stirring. The organic
phase was separated and washed with deionized water. The organic phase was again separated,
dried over anhydrous Na2SO4, filtered and concentrated to give the product 22 as a colorless oil
that was used in the next step without further purification (6.03 g, 96%); 1H NMR (CDCl3) δ
4.25 (t, 2H), 3.28 (t, 2H), 3.02 (s, 3H), 2.84 (s, 3H), 1.78 (m, 2H), 1.66 (m, 2H), 1.44 (s, 9H).
[4-(4-Amino-butylamino)-butyl]-methyl-carbamic acid tert-butyl ester, 23.
Putrescine (9.45 g, 107 mmol) was dissolved in acetonitrile (200 mL) with K2CO3 (14.79 g, 107
mmol) and stirred under N2. Mesylate 22 (6.03 g, 21.4 mmol) dissolved in acetonitrile (60 mL)
was added dropwise over 30 min while stirring under N2. After 30 min, the reaction mixture was
brought to reflux and stirred overnight. The reaction mixture was then cooled, solid K2CO3 was
filtered off and the filtrate concentrated in vacuo. The residue was redissolved in CH2Cl2 (200
mL) and washed six times with sat. aqueous Na2CO3 to remove the unreacted putrescine. The
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organic layer was then dried over anhydrous Na2SO4, filtered, and concentrated to give the
product 23 as a clear oil that was used in the next step without further purification, yield: 5.31 g
(90%); 1H NMR (CDCl3) δ 3.21 (t, 2H), 2.84 (s, 3H), 2.71 (t, 2H), 2.62 (t, 4H), 1.40-1.60 (m,
17H).
[4-(4-{[10-({4-[4-(tert-Butoxycarbonyl-methyl-amino)-butylamino]-butylamino}methyl)-anthracen-9-ylmethyl]-amino}-butylamino)-butyl]-methyl-carbamic acid tert-butyl
ester, 24. To a stirred solution of 23 (100 mg, 0.37 mmol) in 25% MeOH/CH2Cl2 (11.5 mL) and
TEA (0.25 mL, 0.831 mmol) under N2 was added a solution of anthracene-9,10dicarboxaldehyde (39.1 mg, 0.166 mmol) in 25% MeOH/CH2Cl2 (8.5 mL). The mixture was
stirred at room temperature overnight until the imine formation was complete (by 1H NMR). The
solvent was removed in vacuo and the solid residue was dissolved in 50% MeOH/CH2Cl2 (15
mL), and the solution was cooled to 0°C. NaBH4 (83.0 mg, 2.19 mmol) was added in small
portions to the solution, and the mixture was stirred at room temperature overnight. The solvent
was removed in vacuo, and the solid residue was dissolved in CH2Cl2 (25 mL) and washed with
10 wt% aqueous Na2CO3 solution (3x15 mL). The organic layer was dried over anhydrous
Na2SO4, filtered and concentrated to give an oily residue. A pale red oil 24 was obtained and
taken onto the next step without further purification (110 mg crude mass); 1H NMR (CDCl3) δ
8.39 (dd, 4H, CH), 7.58 (dd, 4H, CH), 4.72 (dd, 4H, CH2), 3.19 (t, 4H, CH2), 2.92 (s, 6H, CH3),
2.84 (t, 8H, CH2), 2.61 (m, 8H, CH2), 1.85 (br s, 4H, NH), 1.41-1.65 (m, 52H).
[4-({4-[(10-{[(4-{[4-(tert-Butoxycarbonyl-methyl-amino)-butyl]-tertButoxycarbonyl-amino}-butyl)-tert-Butoxycarbonyl-amino]-methyl}-anthracen-9-
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ylmethyl)-tert-Butoxycarbonyl-amino]-butyl}-tert-Butoxycarbonyl-amino)-butyl]-methylcarbamic acid tert-butyl ester, 25. A solution of 24 (110 mg crude mass from previous step) in
TEA/MeOH (1:7 v/v, 50 mL) was stirred at 0°C for 15 min. A solution of di-tert-butyl
dicarbonate (184 mg, 0.844 mmol) in MeOH (10 mL) was added dropwise over 10 min. The
mixture was stirred for 1 h under a N2 atmosphere. The temperature was allowed to gradually
rise to room temperature, and the solution was stirred overnight. The solution was evaporated
under reduced pressure, and the residue was dissolved in CH2Cl2 and washed with deionized
water. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated
to give a clear oil. The oil was purified by flash column chromatography Rf =0.21(20%
acetone/80% hexane) to afford 25 (80 mg, 42% over 2 steps); 1H NMR (CDCl3) δ 8.44 (dd, 4H,
CH), 7.57 (dd, 4H, CH), 5.58 (dd, 4H, CH2), 3.19 (s, 6H, CH3), 2.91-3.11 (t, , 6H, CH2), 2.80 (m,
12H, CH2), 1.85 (bs, 2H, NH), 1.10-1.75 (m, 68H). HRMS (FAB) m/z calc for C64H104N6O12 (H
+ M)+ 1149.5436, found 1148.7604. Elemental Analysis: C64H104N6O12·2 H2O theory C: 64.84,
H: 9.18, N: 7.09; found C: 64.89, H: 9.13, N: 6.81.
[4-(4-Benzyloxycarbonylamino-butylamino)-butyl]-methyl-carbamic acid tert-butyl
ester, 26. (4-Amino-butyl)-carbamic acid benzyl ester (2.21 g, 9.93 mmol) was dissolved in
acetonitrile (100 mL) with K2CO3 (6.40 g, 46.3 mmol) and stirred under N2. Mesylate 22 (2.35 g,
8.33 mmol) dissolved in acetontrile (25 mL) was added dropwise over 30 min while stirring
under N2. After 30 min of stirring, the reaction mixture was brought to reflux and run overnight.
The reaction mixture was then cooled, and solid K2CO3 was filtered off and the filtrate was
concentrated in vacuo. The residue was redissolved in CH2Cl2 (100 mL) and washed with sat.
Na2CO3 (aq) (3x60 mL). The organic layer was then separated, dried over anhydrous Na2SO4,
44

filtered, and concentrated to give the product 26 as a colorless oil. The oil was purified by flash
column chromatography Rf=0.29 (0.2% NH4OH/15% iPrOH/84.8% CH2Cl2) to afford 26 (760
mg, 20%); 1H NMR (CDCl3) δ 7.28 (m, 5H), 5.09 (s, 2H), 3.19 (s, 4H), 2.80 (s, 3H), 2.59 (t,
4H), 1.4-1.6 (m, 17H).
(4-Benzyloxycarbonylamino-butyl)-[4-(tert-butoxycarbonyl-methyl-amino)-butyl]carbamic acid tert-butyl ester, 27. A solution of 26 (760 mg, 1.87 mmol) in TEA/MeOH (1:7
v/v, 100 mL) was stirred at 0°C for 15 min. A solution of di-tert-butyl dicarbonate (407 mg, 1.87
mmol) in MeOH (20 mL) was added dropwise over 10 min. The mixture was stirred for 1 h
under N2 atmosphere at room temperature. The solution was evaporated under reduced pressure,
and the residue was dissolved in CH2Cl2 (50 mL) and washed with deionized water (3x30 mL).
The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated to give
a colorless oil 27 (940 mg, 99%). The oil was taken to the next step without further purification.
1

H NMR (CDCl3) δ 7.28 (m, 5H), 5.10 (s, 2 H), 3.18 (s, 8H), 2.81 (s, 3H), 1.4-1.6 (m, 26 H).
tert-Butyl (4-((4-aminobutyl)(tert-butoxycarbonyl)amino)butyl)(methyl)carbamate,

28. To a stirred solution of 23 (5.54 g, 20.3 mmol) and anhydrous Na2SO4 (23 g, 160 mmol) in
25% MeOH/CH2Cl2 (500 mL) at room temperature was added salicylaldehyde (2.47 g, 20.3
mmol) dropwise over 5 min, and the reaction was allowed to stir for 1 hour. After 1H NMR
showed complete conversion to the imine, the reaction was cooled to 0°C and di-tert-butyl
dicarbonate (4.42 g, 20.3 mmol) was added as a solid. The reaction was then stirred for 45 min at
room temperature. The volatiles were then removed under reduced pressure and the residue was
redissolved in absolute EtOH (400 mL) and cooled to 0°C. A 1 M HCl (30 mL) solution was
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added dropwise and then the reaction was warmed to room temperature and allowed to stir for 2
hours. After hydrolysis was complete, the volatiles were removed under reduced pressure, and
the residue was washed 3 times with deionized water to remove excess salicylaldehyde. The
residue was then redissolved in CH2Cl2 and washed 3 times with sat. aq. Na2CO3 to generate the
free base. The free base was then purified by column chromatography Rf=0.28 (1% NH4OH/10%
MeOH/89% CH2Cl2) to give 28 as a pale yellow oil (3.55 g, 47%). 1H NMR (CDCl3) δ 3.18 (t,
6H), 2.82 (s, 3H), 2.71 (t, 2H), 1.25-1.65 (m, 26H); 13C NMR (CDCl3) δ 155.8, 155.5, 79.3, 79.2,
48.6, 48.0, 49.6, 41.0, 40.7, 34.1, 28.6, 28.4, 28.0, 25.8, 25.2, 24.8.
Di-tert-butyl (((anthracene-9,10-diylbis(methylene))bis(azanediyl))bis(butane-4,1diyl))bis((4-((tert-butoxycarbonyl)(methyl)amino)butyl)carbamate), 29. To a stirred solution
of amine 28 (600 mg, 1.61 mmol) in 25% MeOH/CH2Cl2 (25 mL) was added a solution of
anthracene-9,10-dicarboxaldehyde (172 mg, 0.73 mmol) in 25% MeOH/CH2Cl2 (20 mL). The
reaction was then stirred at room temperature under N2 overnight. After complete imine
formation was determined by 1H NMR, the solvents were then removed in vacuo and the residue
was redissolved in 50% MeOH/CH2Cl2 (25 mL). The solution was then cooled to 0°C followed
by addition of NaBH4 (166 mg, 4.38 mmol) in small portion and the mixture was stirred at room
temperature for 2 hours. After complete reduction, the solvents were removed in vacuo and the
residue was redissolved in CH2Cl2 and washed three times with aqueous Na2CO3, then dried over
Na2SO4, filtered, and concentrated in vacuo to give 29 as a yellow oil (505 mg, 73%). Rf=0.28
(6% MeOH/0.5% NH4OH/93.5% CH2Cl2); 1H NMR (CDCl3) δ 8.37 (dd, 4H), 7.53 (dd, 4H),
4.70 (s, 4H), 3.19 (t, 12H), 2.89 (t, 4H), 2.81 (s, 6H), 1.57-1.44 (m, 52H); 13C NMR (CDCl3) δ
155.8, 155.6, 132.1, 130.1, 125.7, 124.9, 79.1, 50.4, 46.9, 46.0, 34.1, 28.5, 27.5. HRMS (FAB)
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m/z calc for C54H88N6O8 (M + H)+ 949.3119; found 949.6736. Elemental Analysis:
C54H88N6O8·0.5 H2O theory C: 67.68, H: 9.36, N: 8.77; found C: 67.78, H: 9.09, N:8.57.
Di-tert-butyl (((((naphthalene-1,4-diylbis(methylene))bis(azanediyl))bis(butane-4,1diyl))bis((tert-butoxycarbonyl)azanediyl))bis(butane-4,1-diyl))bis(methylcarbamate), 30.
Yellow oil (55%), Rf=0.29 (10% MeOH/0.5% NH4OH/89.5% CH2Cl2); 1H NMR (CDCl3) δ 8.21
(dd, 2H), 7.52 (dd, 2H), 7.71 (s, 2H), 4.22 (s, 4H), 3.19 (t, 12H), 2.81 (s, 3H), 2.75 (t, 4H), 1.311.62 (m, 52H); 13C NMR (CDCl3) δ 155.8, 155.6, 135.5, 132.2, 125.8, 125.6, 124.4, 79.2, 79.1,
51.8, 49.8, 46.9, 34.1, 28.5, 27.5. m/z calcd for C50H86N6O8 (M + H)+ 899.6507; found 899.6601.
Elemental Analysis: C50H86N6O8 theory C: 66.78, H: 9.64, N: 9.35; found C: 66.55, H: 9.61, N:
9.13.
Di-tert-butyl (((1,4-phenylenebis(methylene))bis(azanediyl))bis(butane-4,1diyl))bis((4-((tert-butoxycarbonyl)(methyl)amino)butyl)carbamate), 31. Yellow oil (74%),
Rf=0.25 (7% MeOH/0.5% NH4OH/92.5% CH2Cl2); 1H NMR (CDCl3) δ 7.27 (s, 4H), 3.76 (s,
4H), 3.20 (t, 12H), 2.83 (s, 6H), 2.64 (t, 4H), 1.53-1.45 (m, 52H); 13C NMR (CDCl3) δ 155.7,
155.5, 138.9, 128.1, 79.0, 53.6, 49.0, 46.9, 34.0, 28.4, 27.3. HRMS (FAB) m/z calc for
C46H84N6O8 (M + H)+ 849.6351; found 849.6423. Elemental Analysis: C46H84N6O8 theory C:
65.06, H: 9.97, N: 9.90; found C: 65.02, H: 9.87, N: 9.69.
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CHAPTER II: POLYAMINE TRANSPORT INHIBITORS: DESIGN,
SYNTHESIS AND COMBINATION THERAPIES WITH
DIFLUOROMETHYLORNITHINE (DFMO)
II.1 Abstract
The development of polyamine transport inhibitors (PTIs) in combination with
difluoromethylornithine (DFMO) presents another strategy to exploit the PTS in cancer. A
success in this area would provide a novel combination therapy which would result in sustained
intracellular polyamine depletion and apoptosis. Prior work demonstrated that a tri-substituted
platform was an efficient design for blocking the import of polyamines. This chapter sought to
identify the key structural aspects of PTIs needed to effectively inhibit polyamine import in
mammalian cells (CHO and L3.6pl) in the presence of the polyamine biosynthesis inhibitor
DFMO.
II.2 Introduction
In aggressive cancers there is a marked increase in polyamine biosynthesis along with the
increase in polyamine uptake.1a, 26 One of the key enzymes involved in polyamine biosynthesis is
the enzyme ornithine decarboxylase (ODC). For cancer cells, ODC is upregulated in an effort to
increase the intracellular pools of polyamines via the biosynthetic pathway and is seen as a
proto-oncogene.27 ODC is the key enzyme necessary for the conversion of ornithine to Put,
which in turn can be converted to the higher polyamines, Spd and Spm.27a In this regard, ODC is
the gateway to polyamine biosynthesis and cell growth. Early efforts to control cell growth led to
the development of a well-tolerated suicide inhibitor of ODC, α-difluoromethylornithine
(DFMO).28 Despite success in inhibiting ODC activity, polyamine transport is often upregulated

48

by cells in order to compensate for the depleted intracellular polyamine pools. Thus, DFMO as a
sole therapeutic was not as effective as initially thought.29
This shortcoming of DFMO has opened the door for the development of polyamine
transport inhibitors (PTIs) in an attempt to block the compensatory response of upregulated
polyamine import. The combination of DFMO and an effective PTI could be very effective in the
overall depletion of intracellular polyamine levels. This has led to the synthesis and
bioevaluation of potential polyamine transport inhibitors and is the subject of Chapter 2.
In order to optimize PTI designs, it was important to understand how the polyamine
transporter functions. As described earlier, there have been two models proposed by Poulin5a and
Belting6, respectively for mammalian polyamine transport. Knowledge of the polyanionic cell
surface target (heparan sulfate) aided the development of poly-cationic PTI agents. In essence,
PTIs which effectively bind to heparan sulfate could also competitively block the import of
exogenous native polyamines. This area has recently been reviewed in detail.30
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Figure II-1. Polyamine Biosynthesis and Transport
Potential PTIs were evaluated in two cell lines to comment on their effectiveness in
blocking native polyamine import. CHO and L3.6pl were chosen for this study. The CHO cell
line was selected for the reasons discussed in Chapter 1, and is known to have an active PTS.7
The L3.6pl cell line is derived from a human metastatic pancreatic cancer cell line, and was
chosen for several reasons. The first reason is that pancreatic cancer is of particular interest due
to the low five-year survival rate of patients with metastatic pancreatic cancer (6%), indicating a
need for new therapies.31 Secondly, it has been identified that an activated K-RAS gene
(identified in approximately 90% of pancreatic cancers) leads to an increase in polyamine uptake
in human cells, and one particular cell line that possesses this K-RAS mutation is L3.6pl.32
Lastly, it has also been found that L3.6pl shows good sensitivity to DFMO and our PTS selective
compound 5a. These factors point to L3.6pl as a good candidate for testing the ability of a
potential PTI to block the import of native polyamines.
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Initially, polyamine-based drug conjugates were developed as potential PTS selective
ligands. A 1,3,5-tri-substituted benzene motif (compound 32), however, demonstrated low Ki
values in L1210 murine leukemia cells while also exhibiting relatively high IC50 values (IC50 >
100 µM) in CHO and CHO-MG cells, and a lack of PTS selectivity.12 The Ki value is important
for determining the relative affinity of these polyamine-based compounds for polyamine
recognition sites on the cell surface. The lower the Ki value, the higher the affinity the compound
for its target. Therefore, presumably the lower the Ki value the better the compound can bind to
the cell surface and block uptake of other polyamine-conjugates. The Ki values were determined
in L1210 cells by competitive uptake with [14C]spermidine.12 This finding for tri-substituted 32
indicated that this compound could have potential as a polyamine transport inhibitor.
Polyamine-based PTIs have been developed, and several lessons have been learned.30
Poulin et.al. developed a series of di-substituted branched polyamine-based PTIs with relatively
low Ki values and demonstrated their ability to inhibit the uptake of putrescine in the T-47D
breast cancer cell line.33 However, these compounds failed to demonstrate effectiveness in
inhibiting uptake of the higher polyamines spermidine and spermine. It was expected that
compounds with lower Ki values (potentially a third polyamine message) could more effectively
inhibit native polyamine import. Burns et al. demonstrated that polyamine-based PTIs could be
very effective through the development of amino acid-spermine conjugates.34 Their initial lead
compound, Lys-Spm (35) proved to be relatively non-toxic while effectively inhibiting
spermidine uptake both in vitro and in vivo.34-35 Due to its published properties as a PTI,
compound 35 was prepared and used as a positive control in both the CHO and L3.6pl
experiments.
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Figure II-2. Structures of compounds 8a and 32-35
A combination therapy where DFMO provides blockade of polyamine biosynthesis
coupled with PTS inhibitors results in sustained intracellular depletion of polyamines and
eventually cell death via apoptosis. This approach represents a novel therapeutic strategy for
cancers with a heavy reliance on the PTS. The finding with 32 then led to the development of
other tri-substituted amine systems like 33a and 33b. Since all three compounds (32, 33a, 33b)
possessed three polyamine messages, the question was then asked whether a third polyamine arm
was needed for PTS inhibition. Interestingly, the bioevaluation of the 1,4-di-substituted xylyl
motif 8a demonstrated high PTS selectivity and a low Ki.12 At first glance, this PTS ligand may
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make a potent PTI as it competes effectively for the cell surface receptors. However, its high
toxicity was an undesired property for the DFMO-PTI combination therapy, which may require
chronic administration. Therefore, PTIs with low toxicity were more desirable. The 1,4-disubstituted system was a toxic PTS ligand and the related 1,3,5-tri-substituted system, 32, was a
relatively non-toxic PTI. Could the 1,3- orientation be a method to modulate drug toxicity? This
question led to the synthesis and bioevaluation of the meta-substituted (1,3-) benzene ring
compounds (34a and 34b). A tandem strategy where DFMO provides blockade of polyamine
biosynthesis coupled with PTS inhibitors results in intracellular depletion of polyamines and
eventually cell death. Investigations of these systems definitively showed that the tri-substituted
design is required for polyamine transport inhibition and low compound toxicity.
II.3 Results and Discussion
Synthesis. The synthesis of 1,3,5-tri-substituted derivative 32 was previously described
by Kaur et al.12, and the synthesis of Lysine-spermine conjugate 35 was previously described by
Burns et al.34a.
The syntheses of the two novel potential polyamine transport inhibitors (PTIs) 33a and
33b began with commercially available 1,3,5-benzenetricarboxylic acid chloride 36. Ironically,
the triamide platform was chosen initially as an alternate synthetic pathway to generate large
quantities of compound 32 but also provided new platforms to evaluate as PTIs. The synthesis
began with the coupling of 36 with Boc-protected polyamine 37a or 37b. Each amine and 36
were mixed together for six hours under mildly basic conditions to give the respective triamides
38a and 38b in moderate yield (56% and 75% respectively). Triamides 38a and 38b were then
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deprotected in the presence of 4 M HCl in EtOH to give the respective compounds 33a and 33b
in high yield.
Triamide 38a was also subjected to LiAlH4 in an attempt to reduce the amide groups to
the desired amine functionality with the expectation to then deprotect the Boc groups to yield trisubstituted system 32. The LiAlH4 reduction, however, was problematic and thus a different
synthetic route needed to be developed to 32. This was previously accomplished by Kaur et al.
by using the tri-aldehyde motif 1,3,5-benzene tricarboxaldehyde, and reductive amination.12
Scheme II-1.a Synthesis of 33a and 33b

a

Reagents: (a) K2CO3, Aliquat, CH2Cl2/H2O; (b) 4 M HCl, EtOH
Di-substituted derivatives 34a and 34b were generated to determine if the third arm

present in the parent compound 32 was necessary for PTS inhibition. This two-arm platform
would also prove to be less challenging synthetically than the parent 32 as dialdehyde 39 is
commercially available, whereas the trialdehyde necessary for the construction of 32 is not.12 As
shown in Scheme II-2, the synthesis began with the reductive amination of aldehyde 39 with the
protected polyamine 37a or 37b.36 Extra caution was taken to dry methanol and NaBH4 so as to
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minimize the generation of alcohol byproducts, which were difficult to separate from the desired
product. This became evident in the purification of 40a, as the mono-alcohol side product and
the excess amine used initially had very similar Rf values to the desired product.
The purification problem was alleviated through the use of a unique TLC solvent system
(hexanes/NH4OH/freshly distilled THF) which ultimately led to the isolation of compound 40a.
Deprotection of 40a gave the final HCl salt 34a. This provided 34a in 24% yield over 3 steps.
The related compound 40b was isolated in 55% yield using the more conventional
CH2Cl2/MeOH/NH4OH TLC solvent system. Finally, 40b was deprotected to give the disubstituted extended amine system 34b in 98% yield. In sum, 34b was generated in 54% yield
over these steps.
Scheme II-2.a Synthesis of 34a and 34b

a

Reagents: (a) 25% MeOH/CH2Cl2, Boc-protected amine 37a36 or 37b36; (b) 50%

MeOH/CH2Cl2, NaBH4; (c) 4 M HCl, EtOH
Biological Evaluation. Once synthesized, the conjugates were screened for their
respective toxicity in L3.6pl, CHO, and CHO-MG* cells. L3.6pl cells were selected as a model
system of human pancreatic cancer and was obtained from Dr. Cheryl Baker at the MD
Anderson Cancer Center in Orlando, FL. CHO cells were chosen along with a mutant PTS
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deficient line (CHO-MG*) in order to comment on polyamine transport selectivity.3c-e, 7 Note:
See Chapter 1 regarding CHO-MG* cell description. The CHO/CHO-MG* results are shown in
Table II-1.
CHO and CHO-MG* Studies. IC50 and MTD Determinations. CHO cells were chosen
along with a mutant cell line (CHO-MG*) to comment on how the synthetic conjugates gain
access to the cells. 3c-e, 7 As discussed earlier, the CHO-MG* cell line is polyamine-transport
deficient and represents a model for alternative modes of entry (other than PTS) including
passive diffusion or use of another transporter. The CHO cell line on the other hand, represents
cells with high polyamine transport activity.8b, 11c A comparison of toxicity in these two CHO
cell lines allowed for a screen that would detect selective use of the polyamine transporter. This
is seen where high utilization of the PTS would be very toxic to CHO cells. In contrast, reduced
toxicity would be expected in CHO-MG* cells.3c-e, 7 Ultimately, a CHO-MG*/CHO IC50 ratio
was determined. A high ratio is expected for highly PTS selective compounds. The results for
this experiment are listed in Table II-1.
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Table II-1. Biological Evaluation of Polyamine Derivatives (32-35) in CHO and CHO-MG*
Cellsa,b,c,d,e
Compound
32
(Trimer44)
33a
(Triamide44)
33b
(Triamide444)
34a
(mBn44)
34b
(mBn444)
35
(Lys-Spm)
a

MTD (µM) in
CHO

CHO-MG* IC50
(µM)

CHO IC50 (µM)

IC50 ratiob

80

>100

>100

ND

>100

>100

>100

ND

1

69.1 (±4.0)

16.0 (±0.7)

4.3

0.01f

30.0 (±0.8)

0.028 (±0.002)

1072

0.01g

13.4 (±0.8)

0.04 (±0.007)

335

>100

>100

>100

ND

CHO and CHO-MG* cells were incubated with 1 mM AG for 24 h prior to drug addition. bThe

ratio denotes the (CHO-MG*/CHO) IC50 ratio, a measure of PTS selectivity. cCells were
incubated for 48 h at 37°C with the respective conjugate. dAll experiments were done in
triplicate. eND: not determined due to the low toxicity in both CHO cell lines. fAt 0.01 µM, 34a
displayed ~90% viability. gAt 0.01 µM, 34b displayed ~90% viability.
The first step in evaluating the above compounds as polyamine transport inhibitors was to
use the CHO and CHO-MG* screen to determine if the compound was a PTS selective agent.
While PTS selective compounds would be competitive inhibitors of polyamine transport, the
goal here was to identify non-toxic PTIs which could be given long-term to patients. In this
regard, toxic PTS-selective agonists were undesired. The maximum tolerated dose (MTD) of
each agent (Table II-1) was determined so that when utilizing the compound as a PTI it could be
stated that the toxicity was attributed to blockade of polyamine import and not to the intrinsic

57

toxicity of the PTI compound. In this regard, non-toxic PTIs provided a higher therapeutic
window as their doses could be significantly elevated to out-compete native polyamines for cell
entry. As discussed earlier, 1,3,5-tri-substituted analogue 32 exhibited a very high IC50 value in
both CHO and CHO-MG* (>100 µM for both), demonstrating it to be fairly non-toxic. This was
in stark contrast to the 1,4-di-substituted platform used for 8a which was very PTS selective
(CHO-MG*/CHO IC50 ratio: 727). This proved to be a very interesting finding as both 32 and 8a
possess near identical Ki values in L1210 cells (0.52 ± 0.11 and 0.49 ± 0.02 respectively).12 This
indicated that while these two compounds bind to the cell surface equally as well, a feature is
present which imparts significant toxicity with 8a and less so with 32.
To better understand these differences, new derivatives were made to investigate whether
the third polyamine message of 32 was needed or if the orientation of these messages is a driver
of this phenomenon. These two questions were answered with the synthesis and evaluation of
34a and 34b as they were designed to most closely mimic 32. These compounds are metasubstituted instead of being para-substituted seen in 8a. With 34a and 34b in hand, they were
evaluated in the CHO and CHO-MG* screen.
The results for 34a and 34b in CHO and CHO-MG* proved to be very interesting and
unexpected. Both compounds were shown to be highly PTS selective as seen in Table II-1.
Compound 34a was seen to be the most PTS selective (CHO-MG*/CHO IC50 ratio: 1072), and
clearly demonstrated that the third polyamine arm of 32 eliminated toxicity. For example, in the
CHO cell line, 32 is >3500-fold less toxic than 34a. Compound 34b was shown to be less PTS
selective (CHO-MG*/CHO IC50 ratio: 335) than its counterpart 34a, demonstrating that the
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longer polyamine message lowered the PTS selectivity of the design. A similar finding was
noted in the comparison of mono-substituted triamines and tetraamines.3d Clearly, tri-substituted
designs were preferred due to their low toxicity. This lesson would also be used in the
development of 33a and 33b as possible polyamine transport inhibitors.
Although 33a was a potential synthetic entry to 32, it also provided a unique opportunity
to evaluate a triamide platform as a PTI agent. The amide motif sequestered one of the amine
groups and altered the positive point charge at this position. In this regard, the triamides
represent a tri-substituted design where the appended polyamine chains are further away from
the aryl core. Triamide 33a effectively displays three putrescine messages whereas triamide 33b
displays three homospermidine messages. Triamide 33b had relatively poor PTS selectivity in
the CHO assay and 34a was not determined due to its low toxicity (Table II-1).
The high transport activity of CHO was also exploited to determine if compounds 32-35
were potent polyamine transport inhibitors. This assay was performed by first inhibiting ODC
and polyamine biosynthesis through the addition of DFMO and reducing cell viability to ~50%.
As stated earlier DFMO is a suicide inhibitor of ODC which in turn leads to an up-regulation of
polyamine transport.29 Once cell viability was reduced to ~50%, Spd, a native polyamine was
added to reproducibly rescue the cells’ viability back to 100%. A potent PTI would be expected
to inhibit Spd entry and the cells treated with DFMO + Spd + PTI would be expected to resemble
the DFMO-only control and gave 50% viability. With this assay in place, the effectiveness of
each potential polyamine transport inhibitor could be tested. DFMO (1 mM) was added to cells
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followed by addition of the putative PTI, followed by addition of 1 µM Spd. The results for this
experiment are shown in Figures II-3, II-4, and II-5.
DFMO Studies. The relative effectiveness of a PTI to block polyamine import was tested
through its ability to block Spd (1 µM) uptake in DFMO treated cells. The rescue event is best
illustrated through the use of Spd as it is found to effectively rescue L1210 and CHO cells from
polyamine based drugs and DFMO.3g For example, the Ki values of the native polyamines (Put,
Spd, Spm) were 208.2, 2.46, and 1.34 µM respectively in L1210 cells.3d While all three of the
native polyamines could be used as a rescue agent, putrescine transport was easily blocked due to
its high Km value and spermine at high doses was toxic to cells.3d In this regard, spermidine was
more challenging to inhibit and was less toxic to cells and thus preferred.
When determining the relative effectiveness of compounds 32-35 in their ability to block
Spd import, 33b, 34a, and 34b were severely limited by their MTD. The MTD as described
earlier is important to be sure the toxicity was due to PTS inhibition and not intrinsic toxicity of
the PTI agent. In CHO, 33b could only be tested up to 1 µM, and 34a and 34b could only be
tested up to 0.01 µM. When tested at their MTD, none of these three compounds could prevent
the rescue effect of Spd (1 µM). Fortunately, the remaining compounds 32, 33a and 35 all fully
blocked the import of Spd (1 µM) at different concentrations. All three of these compounds
showed a dose dependent response in their abilities to block Spd import. For example, as shown
in Figure II-3, increasing levels of 32 provided decreased viability in the presence of DFMO (1
mM) and a typical rescuing dose of Spd (1 µM).
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In a head to head comparison of 32, 33a, and 35 in CHO, compound 32 proved to be the
superior inhibitor of Spd import. In CHO, this became most evident at 1 µM PTI, where cell
viability is 50% for 32 and cell viability is at 100% for both 33a and 35 at the same
concentration. This clearly demonstrates that 32 is better at blocking Spd import and is the most
potent of the series. Compounds 33a and 35 are also effective inhibitors of Spd but required
much higher concentrations (60 µM and 6 µM respectively) to be effective.
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Compound 32

Figure II-3. Ability of 32 (Trimer44) to prevent Spd rescue of DFMO treated CHO cellsa,b,c
a

Cells were incubated for 48 h at 37°C with the respective conjugate, DFMO (1 mM) and Spd (1

µM). b1 mM AG was incubated with cells for 24 h prior to drug addition. cColumns 4-9 represent
experiments with DFMO (1 mM), Spd (1 µM) and increasing concentrations of 32.
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Figure II-4. Ability of 33a (Triamide44) to prevent Spd rescue of DFMO treated CHO cellsa,b
a

Cells were incubated for 48 h at 37°C with the respective conjugate, DFMO (1 mM) and Spd (1

µM). b1 mM AG was incubated with cells for 24 h prior to drug addition. cColumns 4-9 represent
experiments with DFMO (1 mM), Spd (1 µM) and increasing concentrations of 33a.
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Figure II-5. Ability of 35 (Lys-Spm) to prevent Spd rescue of DFMO treated CHO cellsa,b
a

Cells were incubated for 48 h at 37°C with the respective conjugate, DFMO (1 mM) and Spd (1

µM). b1 mM AG was incubated with cells for 24 h prior to drug addition. cColumns 4-9 represent
experiments with DFMO (1 mM), Spd (1 µM) and increasing concentrations of 35.
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L3.6pl Studies. IC50 and MTD Determinations. Compounds 32-35 were also tested in the
metastatic human pancreatic cancer cell line, L3.6pl. This cell line was also chosen due to its KRAS mutation which has been linked to increased polyamine uptake.32b, 37 This increase in
polyamine uptake lends itself to being targeted by polyamine transport inhibitors. The
combination of DFMO and an effective PTI would allow for decreased polyamine levels in these
cells ultimately leading to cell death. When compounds 32-35 were initially tested in L3.6pl,
their IC50 values followed the same trend as seen in CHO. The two main lessons learned in
L3.6pl were the same as in CHO. First, increased polyamine length (33a vs. 33b and 34a vs.
34b) led to increased toxicity. Second, given the same orientation of the benzene ring, the two
polyamine messages of 34a increased toxicity compared to the three polyamine chains of 32.
These findings in CHO/CHO-MG* and L3.6pl identified as potential polyamine transport
inhibitors to be used in combination with DFMO.
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Table II-2. Biological Evaluation of Polyamine Derivatives (32-35) in L3.6pl cellsa,b,c
Compound
32
(Trimer44)
33a
(Triamide44)
33b
(Triamide444)
34a
(mBn44)
34b
(mBn444)
35
(Lys-Spm)
a

MTD (µM) in L3.6pl

L3.6pl IC50 (µM)

10

66.5 (±2.4)

>100

>100

1

15.7 (±0.8)

0.1d

52.2 (±2.0)

0.01e

7.5 (±0.4)

>100

>100

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition.bCells were

incubated for 48 h at 37°C with the respective conjugate.cAll experiments were done in triplicate.
d

At 0.1 µM, 34a displayed 108% viability. eAt 0.01 µM, 34b displayed 97% viability.
DFMO Studies. In L3.6pl, 33b could only be tested up to 1 µM, 34a exhibited a MTD of

0.1 µM, and 34b proved to be very toxic with a MTD at a dose limiting 0.01 µM. Again, when
these compounds (33b, 34a, and 34b) were tested at their MTD in L3.6pl, they were
unsuccessful in inhibiting the uptake of Spd (1 µM). These results further illustrate the need for
PTIs with low toxicity and high MTD values.
In L3.6pl, 32 and 35 were effective inhibitors of Spd import at 10 µM, where 33a was not
as effective at the same concentration. As shown in Figures II-6, II-7 and II-8, 32 was the
superior PTI as it gave 52% viability at 4 µM, whereas 35 gave 75% viability at the same 4 µM
dose. Compound 33a proved to be far less effective as it was not able to approach the 50%
viability mark when dosed even up to 100 µM.
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Figure II-6. Ability of 32 (Trimer44) to prevent Spd rescue of DFMO treated L3.6pl cellsa.b,c
a

Cells were incubated for 48 h at 37°C with the respective conjugate (32), DFMO (5 mM) and

Spd (1 µM). b250 µmM AG was incubated with cells for 24 h prior to drug addition. cColumns 49 represent experiments with DFMO (5 mM), Spd (1 µM) and increasing concentrations of 32.
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Figure II-7. Ability of 33a (Triamide44) to prevent Spd rescue of DFMO treated L3.6pl cellsa,b,c.
a

Cells were incubated for 48 h at 37°C with the respective conjugate, DFMO (5 mM) and Spd (1

µM). b250 µmM AG was incubated with cells for 24 h prior to drug addition. cColumns 4-9
represent experiments with DFMO (5 mM), Spd (1 µM) and increasing concentrations of 33a.
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Figure II-8. Ability of 35 (Lys-Spm) to prevent Spd rescue of DFMO treated L3.6pl cellsa.b,c
a

Cells were incubated for 48 h at 37°C with the respective conjugate, DFMO (5 mM) and Spd (1

µM). b250 µmM AG was incubated with cells for 24 h prior to drug addition. cColumns 4-9
represent experiments with DFMO (5 mM), Spd (1 µM) and increasing concentrations of 35.
II.4 Summary
These Spd import inhibition experiments indicate that a platform with three
homospermidine messages provided the most potent PTI of the series evaluated. As stated
earlier, the di-substituted (meta-substituted) analogues 34a and 34b were toxic PTS selective
ligands which limited their application as PTIs. Their ability to be competitive inhibitors of
polyamine transport could not be demonstrated in the DFMO + Spd assay due to their low MTD
values. In short, these compounds proved to be too toxic in both CHO and L3.6pl to test high
enough doses to outcompete Spd (1 µM). Therefore, the third polyamine arm was shown to be a
key part of the PTI design in terms of its ability to block the import of native polyamines to
retain a low toxicity profile.
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Another key in the development of potential PTIs, is the influence of the polyamine
message length on the toxicity of the compound. Initially it was thought that since the longer
native polyamine chains (i.e. spermine) exhibit lower Ki values, they should be superior PTIs.
However, 33a-b and 34a-b demonstrated that this was not the case due to the toxicity of
tetraamines. Both of the conjugates with the longer polyamine message exhibited a greater level
of toxicity which translated to a very small therapeutic window for each compound. While it is
possible that both of these compounds could in fact block the import of Spd more effectively
than their shorter polyamine counterparts, their low MTD did not allow for this evaluation at
doses which outcompeted Spd (1 µM). In summary, several factors were identified for potent
PTIs: a) triamine arms provided decreased toxicity and a presumed higher therapeutic window;
b) the distance of the triamine from the aryl core also played a role as 33b represents three
homospermidine messages surrounding an aryl core similar to 32. However, these polyamine
messages are further away from each other and reside at five bonds further away from the aryl
platform. This motif leads to higher toxicity and reduces the therapeutic window available to the
triamide system, 33b. In this regard, compound 32 represents an optimized PTI and was clearly
the most potent PTI evaluated.
II.5 Experimental
II.5.1 Materials.
Silica gel (32-63 µm) and chemical reagents were purchased from commercial sources
and used without further purification. All solvents were distilled prior to use. All reactions were
carried out under an N2 atmosphere. 1H and 13C spectra were recorded at 400 or 75 MHz,
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respectively. TLC solvent systems were listed as volume percents, and NH4OH referred to
concentrated aqueous ammonium hydroxide. All tested compounds provided satisfactory
elemental analyses.
II.5.2 Biological Studies.
CHO and CHO-MG* cells were grown in RPMI 1640 medium supplemented with 10%
fetal calf serum and 1% penicillin/streptomycin. Note: the media must contain L-proline
(2µg/mL) for proper growth of the CHO-MG* cells. L3.6pl cells were grown in RPMI 1640
medium supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were grown at
37°C under a humidified 5% CO2 atmosphere. Aminoguanidine (1 mM for CHO and CHOMG*, and 250 µM for L3.6pl) was added to the growth medium to prevent oxidation of the
drugs by the enzyme (bovine serum amine oxidase) present in calf serum. Cells in early to midlog phase were used.
IC50 Determinations. Cell growth was assayed in sterile 96-well microtiter plates
(Costar 3599, Corning, NY, USA). CHO and CHO-MG* cells were plated at 10,000 cells/mL.
L3.6pl cells were plated at 5,000 cells/mL. Drug solutions (10µL per well) of appropriate
concentration were added after an overnight incubation for each CHO cell line (90 µL of cell
suspension used). After exposure to the drug for 48 h, cell growth was determined by measuring
formazan formation from 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulphenyl)-2H-tetrazolium, inner salt (MTS) using a SynergyMx Biotek microplate reader for
absorbance (490 nM) measurements.24
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II.5.3 Synthetic Procedures and Characterization
N1,N3,N5-tris(4-((4-aminobutyl)amino)butyl)benzene-1,3,5-tricarboxamide (33a). A
solution of Boc-protected 38a (910 mg, 0.67 mmol) was dissolved in absolute ethanol (70 mL)
and stirred at 0°C for 10 min. A 4 M HCl solution (40 mL, 160 mmol) was added to the reaction
mixture dropwise and stirred for at 0°C for 30 min and then at room temperature overnight. The
solution was concentrated in vacuo to give 33a as a white solid (625 mg, 99%); 1H NMR (D2O)
δ 8.28 (s, 3H), 3.45 (t, 6 H), 3.14 (q, 12H), 3.07 (t, 6H), 1.78 (m, 24H); 13C NMR (D2O) δ 172.0,
138.0, 131.8, 50.3, 49.9, 42.4, 41.8, 28.6, 27.0, 26.1, 25.8. HRMS (FAB) m/z calc for
C33H72Cl9N9O3 (M + H)+ 915.7198, found 915.4366. Elemental Analysis: C33H72Cl9N9O3·3.5
H2O theory C: 43.28, H: 8.37, N: 13.77; found C: 43.47, H: 8.32, N: 13.55.
N1,N3,N5-tris(4-((4-((4-aminobutyl)amino)butyl)amino)butyl)benzene-1,3,5tricarboxamide nonahydrochloride (33b). Light pink solid, 84%. 1H NMR (D2O) δ 8.29 (s,
3H), 3.46 (t, 6H), 3.15 (24 H), 3.05 (t, 6H), 1.79 (m, 36H); 13C NMR (D2O) δ171.8, 137.8, 131.9,
50.6, 49.6, 42.4, 41.5, 27.1, 28.8, 27.1, 26.8, 25.8. HRMS (FAB) m/z calc for C45H91N12O3 (M +
H)+ 847.7337, found 847.7332. Elemental Analysis: C45H99Cl9N12O3·6 H2O theory C: 42.11,
H:8.72, N:13.10; found C:42.16; H: 8.34, N: 12.94.
N1,N1'-(1,3-phenylenebis(methylene))bis(N4-(4-aminobutyl)butane-1,4-diamine)
(34a). Compound 40a (174 mg, 0.21 mmol) was dissolved in EtOH (30 mL) and stirred at 0°C
for 10 min, and then a 4 M HCl solution (12 mL, 48 mmol) was then added dropwise and stirred
for 30 min. The temperature was then allowed to rise to room temperature and the solution was
then stirred under N2 for four hours. The solvents were then removed in vacuo and the remaining
white solid was washed three times with hexanes to remove BHT. The hexanes were then filtered
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away to give a white solid (80 mg, 24% over 3 steps). 1H NMR (D2O) δ 7.57 (s, 3H), 7.55 (s,
1H), 4.26 (s, 4H), 3.20-3.01 (m, 16H), 1.76 (m, 16H); 13C NMR (D2O) δ 134.7, 133.9, 133.8,
133.0, 53.6, 49.8, 49.5, 41.7, 26.8, 25.7. HRMS (FAB) m/z calc for C24H48N6 (M + H)+
421.3940, found 421.4013. Elemental Analysis: C24H54Cl6N6·0.75 H2O theory C: 44.15, H: 8.57,
N: 12.87; found C: 44.07, H: 8.57, N:12.71.
N1,N1'-(1,3-phenylenebis(methylene))bis(N4-(4-((4-aminobutyl)amino)butyl)butane1,4-diamine) (34b). Compound 40b (130 mg, 0.11 mmol) was dissolved in EtOH (10 mL) and
stirred at 0°C for 10 min, and a 4 M HCl solution (6 mL, 24 mmol) was added dropwise and
stirred for 30 min. The temperature was then allowed to rise to room temperature and the
solution was stirred under N2 for four hours. The solvents were then removed in vacuo to give a
white solid (95 mg, 98%). 1H NMR (D2O) δ 7.59-7.57 (m, 4H), 4.30 (s, 4H), 3.17-3.04 (m, 24H),
1.79-1.77 (m, 24H); 13C NMR 187.9, 134.4, 133.8, 133.7, 132.9, 53.4, 49.6, 49.3, 41.5, 26.6,
25.5. HRMS (FAB) m/z calc for C32H66N8 (M + H)+ 563.5410, found 563.5483. Elemental
Analysis: C32H74Cl8N8·0.5 H2O theory C: 42.54, H: 8.37, N: 12.40; found C: 42.57, H: 8.63, N:
12.07.
(S)-2,6-diamino-N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)hexanamide
(35). 1H NMR (D2O) δ 3.92 (t, 1H), 3.38 (m, 1H), 3.27 (m, 1H), 3.12 (m, 10H), 2.91 (t, 2H), 2.18
(m, 2H0, 1.89 (m, 4H), 1.77 (m, 4H), 1.71 (m, 2H), 1.39 (m, 2H); matched literature values.34
HRMS (FAB) m/z calc for C16H43Cl5N6O (M + H)+ 331.3180, found 331.3175. Elemental
Analysis: C16H43Cl5N6O·1 H2O theory C: 36.20, H: 8.54, N: 15.83, found C: 36.45, H: 8.66, N:
15.58.
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[4-(3,5-Bis-{4-[tert-butoxycarbonyl-(4-tert-butoxycarbonylamino-butyl)-amino]butylcarbamoyl}-benzoylamino)-butyl]-(4-tert-butoxycarbonylamino-butyl)-carbamic acid
tert-butyl ester (38a). A solution of (4-amino-butyl)-(4-tert-butoxycarbonylamino-butyl)carbamic acid tert-butyl ester 37a (1.80 g, 5.01 mmol) and CH2Cl2 (12 mL) was prepared. A
solution of K2CO3 (1.65 g, 11.94 mmol) and water (20 mL) was added to the original mixture.
Aliquat (0.10 mL) was added and the mixture was cooled to 0°C. 1,3,5-Benzenetricarboxylic
acid chloride 36 (400 mg, 1.51 mmol) in CH2Cl2 (24 mL) was added dropwise to the original
mixture and allowed to gradually warm and stir vigorously at room temperature for 6 hours.
After the reaction was complete (by 1H NMR), the solvents were removed in vacuo, and the
residue was redissolved in CH2Cl2. The organic layer was then washed with 0.1 M HCl (24 mL),
followed by deionized H2O (24 mL), and saturated aq. Na2CO3 (24 mL). The organic layer was
then separated, dried over Na2SO4, filtered, and concentrated to give a crude solid which was
then purified by flash column chromatography to afford 38a (1.05 g, 56%) as a white solid
(Rf=0.25; 4% MeOH/96% CH2Cl2); 1H NMR (CDCl3) δ 8.41 (s, 3H), 4.75 (br s, 3H), 3.49 (m,
6H), 3.23-3.06 (m, 18H), 2.78-1.30 (m, 78H); 13C NMR (CDCl3) δ 166.5, 156.1, 155.7, 135.2,
128.5, 79.3, 78.9, 46.6, 40.1, 39.8, 28.4, 27.3, 26.4. HRMS (FAB) m/z calc for C63H111N9O15 (M
+ Na)+ 1256.8092, found 1256.8105. Elemental Analysis: C63H111N9O15·1 H2O theory C: 60.41,
H: 9.09, N: 10.06; found C: 60.40, H: 9.16, N: 9.90.
[4-(3,5-Bis-{4-[tert-butoxycarbonyl-(4-tert-butoxycarbonyl)-(4-tertbutoxycarbonylamino-butyl)-amino]-butylcarbamoyl}-benzoylamino)-butyl]-(4-tertbutoxycarbonylamino-butyl)-carbamic acid tert-butyl ester (38b). A similar procedure was
used for 38b. White solid, 75%. 1H NMR (CDCl3) δ 8.19 (s, 3H), 3.42 (t, 6H), 3.17 (t, 30H),
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1.71-1.41 (m, 117H); 13C NMR (CDCl3) δ 166.4, 156.2, 155.7, 135.4, 128.9, 79.5, 46.8, 45.8,
41.2, 40.5, 39.5, 29.1, 28.5, 27.6, 26.5. Elemental Analysis: C90H162N12O21 theory C: 61.83, H:
9.34, N: 9.61; found C: 61.64, H: 9.37, N: 9.38.
Di-tert-butyl (((1,3-phenylenebis(methylene))bis(azanediyl))bis(butane-4,1diyl))bis((4-((tert-butoxycarbonyl)amino)butyl)carbamate) (40a). In order to maximize the
yield, MeOH was dried and distilled prior to this reaction. To a stirred solution of N1,N6-dibochomospermidine (566 mg, 1.58 mmol) in 25% MeOH/CH2Cl2 (20 mL) was added a solution of
1,3-benzene dicarboxaldehyde 39 (69.9 mg, 0.52 mmol) in 25% MeOH/CH2Cl2 (15 mL). The
reaction was then stirred at room temperature under N2 overnight. After imine formation was
complete (by 1H NMR), the solvents were removed in vacuo and the residue was redissolved in
50% MeOH/CH2Cl2 (25 mL). The solution was then cooled to 0°C followed by addition of predried NaBH4 (118 mg, 3.13 mmol) in small portions and the mixture was stirred at room
temperature under N2 for 2 hours. The solvents were then removed under reduced pressure and
the residue was redissolved in CH2Cl2 and washed three times with aqueous Na2CO3. The
organic layer was separated, dried over Na2SO4, filtered, and concentrated in vacuo. After
column chromatography (Rf=0.25, 25% hexanes/0.1% NH4OH/74.9% THF, see note below),
compound 40a was isolated as a mixture with BHT and was deprotected without further
purification. 1H NMR (CDCl3) δ 7.26-7.15 (m, 4H), 3.62 (s, 4H), 3.14 (t, 12H), 2.58 (t, 4H),
1.58-1.27 (m, 16H); 13C NMR (CDCl3) δ 155.0, 154.5, 139.5, 126.9, 78.1, 66.9, 53.0, 48.2, 45.6,
39.2, 26.8, 25.8, 24.5. Note: The BHT impurity could be avoided by pre-distilling the THF prior
to chromatography.
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Di-tert-butyl (((1,3-phenylenebis(methylene))bis(azanediyl))bis(butane-4,1diyl))bis((4-((tert-butoxycarbonyl)(4-((tertbutoxycarbonyl)amino)butyl)amino)butyl)carbamate) (40b). To a stirred solution of
N1,N6,N11-triBoc-homospermine (705 mg, 1.33 mmol) in 25% MeOH/CH2Cl2 (20 mL) was
added a solution of 1,3-benzene dicarboxaldehyde 39 (52.3 mg, 0.39 mmol) in 25%
MeOH/CH2Cl2 (15 mL). The reaction was then stirred at room temperature under N2 overnight.
After imine formation was complete by 1H NMR, the solvents were removed in vacuo and the
residue was redissolved in 50% MeOH/CH2Cl2 (25 mL). The solution was then cooled to 0°C
followed by addition of NaBH4 (88.5 mg, 2.34 mmol) in small portions and the mixture was
stirred at room temperature under N2 for 2 hours. The solvents were then removed under reduced
pressure and the residue was redissolved in CH2Cl2 and washed three times with aqueous
Na2CO3. The organic layer was separated, dried over Na2SO4, filtered, and concentrated in
vacuo. After column chromatography (Rf=0.31 (10% MeOH/1% NH4OH/89% CH2Cl2)),
compound 40b was isolated as a colorless oil (240 mg, 53%) 1H NMR (CDCl3) δ 7.32-7.19 (m,
4H), 3.77 (s, 4H), 3.15 (t, 20H), 2.65 (t, 4H), 1.60-1.44 (m, 78H); 13C NMR (CDCl3) δ 156.0,
155.5, 140.5, 128.4, 127.8, 126.7, 79.1, 54.0, 49.3, 46.9, 46.6, 40.2, 28.5, 27.4, 26.1. HRMS
(FAB) m/z calc for C62H114N8O12 (M + H)+ 1163.8629, found 1163.8629. Elemental Analysis:
C62H114N8O12 theory C: 64.00, H: 9.87, N: 9.63; found C: 64.24, H: 9.96, N: 9.82.
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CHAPTER III: INVESTIGATION OF ANTI-METASTATIC AGENTS
PREDICATED ON DIHYDROMOTUPORAMINE C AND ITS
DERIVATIVES
III.1 Abstract
The motuporamine family of natural products are of biological interest due to their
unique anti-migration and anti-angiogenic properties. Previous work has demonstrated some of
the key structural aspects of these compounds necessary to maintain their biological activity.
These included a preferred macrocycle ring size (15-membered ring), a preferred degree of
unsaturation (zero) within the heterocycle and a norspermidine motif. This chapter discusses the
development of new motuporamine analogues which modulate the cytotoxicity of this drug class
while simultaneously enhancing their anti-migration ability. In summary, by incrementally
moving the polyamine chain outside the ring, new systems were discovered which doubled the
anti-migration potency and reduced the toxicity by 29-fold. The development of non-toxic antimetastatic agents would have direct application in the treatment of human cancers.
III.2 Introduction
In 1998, Andersen et al reported the discovery of the motuporamine family of
compounds from the sea sponge Xestospongia exigua off the coast of Motupore Island in Papua
New Guinea.38 These compounds were of particular interest as they each possessed a large
macrocycle tethered to a norspermidine (3,3-triamine) message (Figure III-1). This drug class
was structurally similar to the anthryl-polyamines previously reported by Phanstiel et.al.10, 38
Biologically, dihydromotuporamine C (44a) proved to be the most interesting as it was highly
cytotoxic to the MDA-231 breast carcinoma cells and had good anti-invasive properties.38-39 Due

74

to the motuporamine compounds exhibiting structural similarities to 5a (Ant44) and other
previously made analogues10, it was thought that they may function in a similar manner to the
anthryl-polyamine conjugates.

Figure III-1. Structures of motuporamine natural products (41, 42, 43, 44a) and
Dihydromotuporamine C mimics (45a and 45b) and Ant44 (5a)
Recently, it has been shown that dihydromotuporamine C (44a) affects the sphingolipid
biosynthetic pathway.40 Baetz et.al initially showed through a genome-wide haploinsufficiency
screen in yeast that dihydromotuporamine C targets sphinoglipid metabolism.40a This was
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demonstrated via the recognized sensitivity of genes LCB1 and TSC10 to the addition of
dihydromotuporamine C. Both are key genes involved in the biosynthesis of sphingosine, which
is a sphingolipid precursor.40a This was the first molecular target described for 44a. The authors
went on to demonstrate that dihydromotuporamine C at 60 µM was able to fully inhibit the
growth of yeast cells.41 However, the addition of an intermediate of the sphingosine biosynthesis
pathway (dihydrosphingosine) to dihydromotuporamine C-treated yeast cells, was able to rescue
this growth inhibition.41 Dihydromotuporamine C was shown to lower the intracellular levels of
ceramide and the addition of exogenous ceramide was able to partially rescue yeast growth
indicating that dihydromotuporamine C directly targets sphingolipid biosynthesis.40 Despite this
finding in yeast, it could not be demonstrated that exogenous ceramide could completely rescue
the effects of dihydromotuporamine C. 40a, b This observation could be explained by
dihydromotuporamine C having multiple targets in human cells or that the rescue event was
limited by the amount of ceramide that could be added as ceramide is known to have proapoptotic properties.40a, b The fact that the less toxic dihydrosphingosine could rescue these cells
is consistent with the latter possibility.
Beyond sphingolipid metabolism, Rho GTPase was also identified as a potential target of
dihydromotuporamine C (44a).40b An increase in Rho signaling has been associated with many
types of cancer.42 This increase in Rho signaling has also seen to play a part in the anti-invasive
action of dihydromotuporamine C.40b, 43 This has been partly explained by a loss of cell polarity
and an increase in adhesion strength caused by Rho activation.40b Another key player in the antimigration ability of dihydromotuporamine C is the activation of integrin signaling, which in turn
leads to the inhibition of tumor migration by activated Rho signaling.40b, 44
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A series of structure activity relationship studies has also helped determine which aspects
of the dihydromotuporamine C (44a) structure provides for its unique biological activity. The
structure of the motuporamines can be broken into two main components: the macrocyclic ring,
and the norspermidine tail. The 15-membered macrocyclic ring is favored over other size rings
as it demonstrated the highest levels of cytotoxicity and invasion inhibition in MDA-MB-231
cells.39a Williams et.al. also showed that the degrees of unsaturation in the ring also dramatically
affected the biological activity of the series, where a saturated ring (completely void of
unsaturation) proved to be the most potent design in terms of anti-migration properties.39a A
carbazole ring substitute also showed promising anti-invasion properties, although it was not as
potent as the parent, dihydromotuporamine C.39a
The other key structural characteristic of the motuporamines is the norspermidine tail. It
was demonstrated that acetylation of the terminal amino group had no effect on the biological
activity of motuporamine C (43), however, acetylation of both amine groups saw a complete loss
of activity.39b This finding suggested the importance of the central secondary amine for high
biological activity.
Previous efforts by Phanstiel et.al. explored the conformational preferences of
dihydromotuporamine C (44a) by computer modeling.45 These experiments demonstrated that
the saturated ring system was conformationally mobile as expected. The orientation of the
polyamine chain off the ring was shown to be critical and helped the authors design new
motuporamine mimics. These mimics were predicated upon anthryl-polyamines. Specifically,
AntNEt33 (45a) had similar preferred molecular conformations as dihydromotuporamine C
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(44a) and was shown to mimic the cytotoxicity of dihydromotuporamine C in CHO and CHOMG cells. Although AntNEt33 (45a) was a good mimic of dihydromotuporamine C in vitro, it
failed to mimic the anti-metastatic properties of dihydromotuporamine C in vivo.
Efforts to append a cell-targeting homospermidine message to this macrocycle
unfortunately resulted in a non-PTS targeting drug with lower cytotoxicity.25 Additional work
demonstrated that this was due to the tertiary amine center at the N1 position. In short, N1ethylation provided a compound with a similar cytotoxicity profile as dihydromotuporamine C.
However, the N1-ethyl group was also shown to dramatically reduce the ability of the drug to
access the PTS for cell entry.45
During studies to explore how 5a and its analogues10 compare in their biological function
to dihydromotuporamine C (44a), 44a was evaluated for its PTS selectivity. In previous studies
compounds that possessed the 3,3-triamine (i.e. norspermidine) message (as seen in 44a)
exhibited poor PTS selectivity while compounds with a 4,4-triamine (i.e. homospermidine)
message exhibited the highest PTS selectivity.10 This led to the synthesis of the parent compound
44a as well as the homospermidine analogue 44b in order to determine if the optimized
polyamine message would provide increased PTS selectivity over the parent. When both of these
compounds were subjected to the CHO/CHO-MG screen, neither demonstrated PTS selectivity
as their CHO-MG/CHO IC50 ratio was found to be 1.25 Due to the presence of the tertiary amine
at the N1 position for 44a and 44b, a structural analogue using anthracene as the macrocycle
(45a) was synthesized with a tertiary amine at the N1 position, and bioevaluation showed an
identical CHO-MG/CHO IC50 ratio of 1.25 This follow-up study using N1-alkylated anthryl-
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polyamines demonstrated that PTS selectivity was dependent upon the N1-substitution pattern.
Evidently, tertiary amine centers at the N1 position inhibit the PTS selectivity of the drug
conjugate, whereas a secondary amine center facilitates PTS selectivity.
Compounds 44a and 44b each possess an amine at the N1 position that is not only a
tertiary amine but also is sterically encumbered by the macrocyclic ring. As stated earlier, a
similar phenomenon was seen when the N1-substitution pattern of anthryl-polyamines is altered
(e.g. Ant44 (5a) vs AntNEt44 (45b)), and poor PTS selectivity was seen upon N1-ethylation.45
When the amine is moved further away from the anthracene core, the PTS selectivity
dramatically increased.10 However, moving it too far away from the anthracene core decreased
PTS selectivity.10 This relationship prompted the question: would moving the polyamine
message of 44a and 44b away from the macrocyclic core subsequently increase the PTS
selectivity? It was also of interest to see if moving the polyamine message also affected the
cytotoxicity and the anti-migration ability of the compound. Chapter 3 addresses these questions
through the synthesis and bioevaluation of compounds 46-47 and their comparison to compounds
44a and 44b. Note that compounds 46 and 47 retain the secondary amine center at the N1
position, which was shown to be an essential element for PTS-targeting.10 Dramatic
improvements were observed. These structural changes resulted in a 29-fold decrease in toxicity
and a doubling of the anti-migration potency of the drug platform.
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Figure III-2. Motuporamine Derivatives (44, 46, 47)
III.3 Results and Discussion
Synthesis. The synthesis of 44a was previously described by Goldring et.al.46, Fürstner
et.al.47, Williams et.al.39a, and Kaur et.al.25, while the synthesis of 44b was previously described
by Kaur et.al.25.
The syntheses of the four remaining compounds began with the synthesis of 46a and 46b.
As shown in Scheme III-1, reductive amination of commercially available ketone 48 with Bocprotected polyamines (49a or 49b)36, 48 gave the respective compounds 50a and 50b in moderate
yield (54% and 75%, respectively). These two compounds were then each treated with 4 M HCl
in EtOH to remove the Boc groups and provided 46a and 46b in high yield (98% and 99%,
respectively). The overall yields for compounds 46a and 46b were 53% and 74%, respectively,
from ketone 48.
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Scheme III-1.a Synthesis of 46a and 46b

a

Reagents: (a) NaBH(OAc)3, AcOH, CH2Cl2; (b) 4 M HCl, EtOH
In contrast, the synthesis of the extended motifs 47a and 47b proved to be more

challenging as the generation of aldehyde 53 was more difficult than initially thought (Scheme
III-2). The first attempt at generating aldehyde 53 was through the use of
(methoxymethyl)triphenylphosphonium chloride in a classic Wittig reaction to generate the vinyl
ether, followed by hydrolysis. Generation of the vinyl ether failed while trying several base
sources (BuLi, NaHMDS, NaH) where only the starting ketone 48 was recovered. The second
attempt utilized Vilsmeier-Haack conditions with POCl3 in DMF to generate (Z)-2chlorocyclopentadec-1-enecarbaldehyde followed by reduction with H2 and Pd/C. The alkene
intermediate was generated fairly smoothly, albeit at 70% conversion. The subsequent reduction
method was unsuccessful at reducing the alkene intermediate to the final desired aldehyde 53.
While it was unclear why these methods failed, steric crowding may have played a role.
After two unsuccessful attempts at generating aldehyde 53, a longer synthetic route was
chosen. This route began with commercially available ketone 48 and a standard Wittig reaction
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with methyltriphenylphosphonium iodide, to generate alkene 51 in 69% yield. Alkene 51 was
then subjected to hydroboration conditions, followed by oxidation of the resultant alcohol with
PCC to generate aldehyde 53 which was used without further purification. Reductive amination
of aldehyde 53 with Boc-protected polyamines 49a and 49b generated 54a and 54b in 36% and
51%, respectively. These Boc-protected compounds were then deprotected with 4 M HCl to give
47a and 47b in 92% and 95% yields, respectively. The overall yields of 47a and 47b were 17%
and 21% respectively from ketone 48.
Scheme III-2.a Synthesis of 47a and 47b

a

Reagents: (a) Ph3PCH3I, BuLi, THF, 0°C; (b) BH3-THF, 0°C then H2O2, 3 M NaOH, RT; (c)

PCC, CH2Cl2; (d) 49a48 or 49b36, NaBH(OAc)3, AcOH, CH2Cl2; (e) 4 M HCl, EtOH
Biological Evaluation. Once synthesized, the conjugates were screened for toxicity in
L3.6pl, CHO, and CHO-MG* cells. L3.6pl cells were selected as a human metastatic pancreatic
cancer cell line. CHO cells were chosen along with a mutant PTS-deficient line (CHO-MG*) in
order to comment on polyamine transport selectivity.3c-e, 7
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CHO and CHO-MG* Studies. IC50 and MTD Determinations. CHO cells were chosen
along with a mutant cell line (CHO-MG*) to comment on how the synthetic conjugates gain
access to the cells. 3c-e, 7 As discussed earlier, the CHO-MG* cell line is polyamine-transport
deficient and represents a model for alternative modes of entry (other than PTS) including
passive diffusion or use of another transporter. The CHO cell line on the other hand, represents
cells with high polyamine transport activity.8b, 11c A comparison of toxicity in these two CHO
cell lines allowed for a screen that would detect selective use of the polyamine transporter. High
utilization of the PTS would be very toxic to CHO cells. However, the CHO-MG* cells should
be less sensitive to drugs which target the PTS. 3c-e, 7 Ultimately, a CHO-MG*/CHO IC50 ratio
was determined to assess PTS selectivity. A high IC50 ratio (>>2) would be observed for PTS
selective compounds. The results obtained with compounds 44, 46, and 47 are shown in Table
III-1.
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Table III-1. Biological Evaluation of Motuporamine Derivatives (44, 46, and 47) in CHO and
CHO-MG* Cellsa,b,c,d
Compound
44a
(Motu33)
44b
(Motu44)
46a
(MotuN33)
46b
(MotuN44)
47a
(MotuCH233)
47b
(MotuCH244)
a

CHO-MG* IC50 (µM)

CHO IC50 (µM)

IC50 ratiob

2.96 (±0.1)

2.90 (±0.2)

1

4.67 (±0.9)

4.38 (±0.3)

1

5.95 (±0.5)

2.84 (±0.2)

2.1

5.18 (±0.9)

4.53 (±0.2)

1

87.3 (±11)

82.9 (±20)

1

45.5 (±1.4)

47.8 (±2.4)

1

CHO and CHO-MG* cells were incubated with 1 mM AG for 24 h prior to drug addition. bThe

ratio denotes the (CHO-MG*/CHO) IC50 ratio, a measure of PTS selectivity. cCells were
incubated for 48 h at 37°C with the respective conjugate. dAll experiments were run in triplicate.
As reported earlier, dihydromotuporamine C (44a) and its analogue 44b did not exhibit
PTS selectivity as their IC50 ratio in the original CHO-MG line and CHO were both 1.25 This was
verified again to be the case in CHO and CHO-MG* as both 44a and 44b exhibited a CHOMG*/CHO IC50 ratio of 1. Low CHO-MG*/CHO IC50 ratios were observed for analogues 46a,
46b, 47a, and 47b demonstrating a general lack of PTS selectivity.
Despite this apparent lack of PTS selectivity, an interesting general trend in cytotoxicity
was observed in both CHO and CHO-MG*. As the amine at the N1 position was moved away
from the macrocyclic core, the cytotoxicity decreased. This was most dramatic for 47a and 47b
where a methylene spacer was present between the amine at the N1 position and the macrocyclic
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core. It is also interesting to note that the 4,4-analogue 47b (CHO IC50: 47.8 µM) was roughly
twice as toxic as the 3,3-analogue 47a (CHO IC50: 82.9 µM).
L3.6pl Studies. IC50 and MTD Determinations. Compounds 44, 46 and 47 were also
tested in the metastatic human pancreatic cancer cell line, L3.6pl.32b, 37 This cell line was chosen
due to its K-RAS mutation which has been linked to increased polyamine uptake.32b, 37 This
increase in polyamine uptake lends itself to being exploited by polyamine-based drug conjugates.
These two features made this cell line an ideal candidate for evaluating potentially antimetastatic polyamine-based drug conjugates.
When compounds 44, 46, and 47 were initially tested in L3.6pl their IC50 values (Table
III-2) were nearly identical to the IC50 values found in CHO and CHO-MG*. These IC50 results
were again interesting as they showed that as the polyamine message was moved away from the
macrocyclic core, the cytotoxicity decreased, and was most evident for 47a and 47b. The MTD
was determined for each of these compounds (Table III-2). This dosing information was
important as it allowed each compound’s anti-migration properties to be assessed at its own
MTD and also at the MTD of the parent compound, 44a (0.6 µM) in subsequent wound healing
assays.
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Table III-2. Biological Evaluation of Motuporamine Derivatives (44, 46, and 47) in L3.6pl
Cellsa,b,c
Compound
44a
(Motu33)
44b
(Motu44)
46a
(MotuN33)
46b
(MotuN44)
47a
(MotuCH233)
47b
(MotuCH244)
a

L3.6pl IC50 (µM)

L3.6pl MTD (µM)

0.99 (±0.07)

0.6

1.8 (±0.2)

1.0

2.8 (±0.2)

2.0

2.8 (±0.1)

2.0

89.4 (±5.4)

80

48.7 (±2.8)

40

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate. cAll experiments were run in triplicate.
Note: Steep cytotoxicity curves were observed and as a result the MTD was often near the
respective IC50 values.
Wound Healing Assay. A wound healing assay was employed to evaluate the antimigration properties of compounds 44, 46, and 47 in L3.6pl cells. This involved growing a
monolayer of L3.6pl cells and then scraping the monolayer with a sterile pipet tip to create a cell
free channel in the middle of the well.49 The experiment was run in 96-well plate format. Wound
healing was measured by time-course imaging of each well using a computer-controlled
microscope with an x,y,z stage which allowed for reproducible imaging over time. Each drug
was evaluated for its dose-dependent inhibition of cell migration. Each compound was evaluated
at its own MTD in order to avoid cytotoxic effects which are well known to bias migration
studies.39a In addition, each compound was also tested at the MTD of 44a (Motu33) to directly
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compare the potency of these compounds at the same concentration. These findings are reported
in Table III-3.
Table III-3. Inhibition of L3.6pl Cell Migration by Compounds 44, 46, and 47a-g
Compound
Control
44a
(Motu33)
44b
(Motu44)
46a
(MotuN33)
46b
(MotuN44)
47a
(MotuCH233)
47b
(MotuCH244)
a

Concentration (µM)
Untreated

% Cell Migration Inhibition
0 (±1.5)

0.6c

20.3 (±1.8)

0.6
1c
0.6
2c
0.6
2c
0.6
80c
0.6
40c

16.7 (±0.8)
29.6 (±4.5)
19.3 (±1.3)
32.9 (±0.1)
31.4 (±4.1)
33.4 (±0.5)
38.4 (±4.2)
44.8 (±2.2)
29.6 (±1.6)
45.3 (±3.7)

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate. cMTD of the respective conjugate. d%
cell migration was determined with ImageJ software50 by determining the area not occupied by
cells (white space upon microscopic examination: WS) and calculated by [((WS at 0 h)-(WS at
48 h))/WS at 0 h]x100%. e% cell inhibition was calculated by [1-(% cell migration at 48 h)/(%
cell migration at 0 h)]x100%. The untreated control cells migrated 48% of the t=0 wound space
f

The microscope was equipped with a computer controlled x,y,z pneumatic stage (Zeiss Stemi

Microscope) which allowed for reproducible imaging of each well over time. gAll experiments
were run in triplicate and averaged to provide the data above.
When the 3,3-triamine containing systems 44a, 46a, and 47a were compared at 0.6 µM, it
was seen that as the N1 amine center was moved away from the macrocylic ring
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(44a→46a→47a), an increase in cell migration inhibition was observed. Compound 47a
(MotuCH233) had the highest inhibition observed in the series. The corresponding 4,4-triamine
series at 0.6 µM showed a dramatic increase in anti-migration ability upon moving the
polyamine outside the ring (44b→46b≈47b). This finding was especially interesting for
compounds 47a and 47b, which both showed MTDs that were much higher than 0.6 µM (>130fold and >60 fold, respectively). In this regard these compounds are much less toxic than the
parent 44a. This large therapeutic window makes these compounds ideal candidates to pursue in
further studies in vivo. All compounds tested in this assay also demonstrated a dose-dependent
response. However, dramatic increases in cell migration inhibition were not observed for higher
doses, suggesting that the target of these compounds may be easily saturated.
The significant difference in cytotoxicity between 47a and 47b suggested that the
polyamine tail, especially norspermidine, provides a means to modulate the cytotoxicity of future
analogues. From a synthetic standpoint, this finding is advantageous as the Boc-protected
norspermidine tail can be produced in fewer steps than its homospermidine counterpart.
Taking pictures of each wound needed to be done under a 2.5x objective in order to view
~95% of each well. Unfortunately, this objective led to some dark areas as seen in Figures III-3
through III-8. This problem was alleviated through the use of the ImageJ software.50 This
software allowed for enhancing the contrast between areas which were occupied by cells versus
areas devoid of cells. In this regard, the software was able to accurately define the edges of each
boundary. These capabilities then allowed for accurate area calculations which are seen in Table
III-3.
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Figure III-3. L3.6pl Cell Migration with 44a (Motu33) via Wound Healing Assaya,b
a

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate.
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Figure III-4. L3.6pl Cell Migration with 44b (Motu44) via Wound Healing Assaya,b,
a

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate.
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Figure III-5. L3.6pl Cell Migration with 46a (MotuN33) via Wound Healing Assaya,b
a

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate.
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Figure III-6. L3.6pl Cell Migration with 46b (MotuN44) via Wound Healing Assaya,b
a

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate.
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Figure III-7. L3.6pl Cell Migration with 47a (MotuCH233) via Wound Healing Assaya,b
a

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate.
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Figure III-8. L3.6pl Cell Migration with 47b (MotuCH244) via Wound Healing Assaya,b
a

L3.6pl cells were incubated with 250 µM AG for 24 h prior to drug addition. bCells were

incubated for 48 h at 37°C with the respective conjugate.
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III.4 Summary
The IC50/MTD determinations coupled with the wound healing assay showed that
moving the polyamine message away from the macrocyclic ring had a profound effect on the
biological properties of the motuporamine compounds. As stated earlier, compounds 44, 46, and
47 did not demonstrate PTS selectivity in the CHO-MG*/CHO screen. Biological evaluation in
L3.6pl, CHO, and CHO-MG* showed that a carbon spacer between the N1-amine and the
macrocylic ring (i.e. 47a and 47b) dramatically reduced the cytotoxicity of this architecture. It
was also demonstrated that a change in polyamine tail from norspermidine to homospermidine
showed a profound effect on cytotoxicity and the magnitude and specificity of this effect
depended on the system investigated. For example, the norspermidine derivative 44a was more
toxic than its homospermidine derivative 44b. The opposite trend was observed for 47a and 47b.
The fact that 46a and 46b had nearly identical toxicities suggests that the type and location of the
appended polyamine chain influences the toxicity of the compound.
The wound healing assay demonstrated that moving the N1-amine away from the
macrocyclic ring not only reduced the cytotoxicity, but also greatly increased the anti-migration
properties. When 47a (MTD: 80 µM) and 47b (MTD: 40 µM) were both dosed at the MTD of
44a (i.e., 0.6 µM), a dramatic increase in anti-migration ability was seen for 47a and 47b relative
to the parent system, 44a. This large therapeutic window suggests that 47a and 47b are
promising drug candidates for inhibiting the migration of aggressive metastatic cancers. These
new leads are relatively non-toxic and are twice as potent as the parent 44a. In summary, new
anti-metastatic drugs were identified for evaluation in future in vivo models of metastatic
cancers.
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III.5 Experimental
III.5.1 Materials.
Silica gel (32-63 µm) and chemical reagents were purchased from commercial sources
and used without further purification. All solvents were distilled prior to use. All reactions were
carried out under an N2 atmosphere. 1H and 13C spectra were recorded at 400 or 75 MHz,
respectively. TLC solvent systems were listed as volume percents, and NH4OH referred to
concentrated aqueous NH4OH. All tested compounds provided satisfactory elemental analyses.
III.5.2 Biological Studies.
CHO and CHO-MG* cells were grown in RPMI 1640 medium supplemented with 10%
fetal calf serum and 1% penicillin/streptomycin. Note: the media must contain L-proline (2
µg/mL) for proper growth of the CHO-MG* cells. L3.6pl cells were grown in RPMI 1640
medium supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were grown at
37°C under a humidified 5% CO2 atmosphere. Aminoguanidine (1 mM for CHO and CHOMG*, and 250 µM for L3.6pl) was added to the growth medium to prevent oxidation of the
drugs by the enzyme (bovine serum amine oxidase) present in calf serum. Cells in early to midlog phase growth were used.
IC50 Determinations. Cell growth was assayed in sterile 96-well microtiter plates
(Costar 3599, Corning, NY, USA). CHO and CHO-MG* cells were plated at 10,000 cells/mL.
L3.6pl cells were plated at 5,000 cells/mL. Drug solutions (10 µL per well) of appropriate
concentration were added after an overnight incubation for each CHO cell line (90 µL of cell
suspension). After exposure to the drug for 48 h, cell growth was determined by measuring
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formazan formation from 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulphenyl)-2H-tetrazolium, inner salt (MTS) using a SynergyMx BioTek microplate reader for
absorbance (490 nM) measurements.24 A 4 h incubation period was used for the MTS assay in
accordance with the manufacturer’s protocol.24
Wound Healing Assay.49 Anti-migratory properties were assayed in 96-well microtiter
plates (Costar 3599, Corning, NY, USA). A stock suspension of L3.6pl cells (5.5x105 cells/mL)
was prepared. L3.6pl cells (90 µL of stock/well) were plated and allowed to grow to a confluent
monolayer (48 h) at 37°C and 5% CO2. Each well was then scraped with a 1 µL sterile pipet tip,
photographed with a Zeiss Stemi Microscope (2.5x objective) (time=0), and then allowed to
incubate for an additional 48 h period (time=48h). Over this 48 h period, the untreated control
migrated to fill approximately 50% of the original wound. At time zero, the respective drug
solutions (10 µL) were added and cell migration monitored after 48 h incubation at 37°C with
5% CO2. After drug exposure for 48 h, respective time=48 h photographs were taken by the
Zeiss Stemi Microscope. These pictures (time=0 and time=48 h) were then compared and
analyzed through the use of ImageJ software50 by calculating the average area invaded by L3.6pl
cells. The results are tabulated in Table III-3.
III.5.3 Synthetic Procedures and Characterization
N1-(3-Aminopropyl)-N3-cyclopentadecylpropane-1,3-diamine (46a). Compound 50a
(450 mg, 0.8 mmol) was first dissolved in EtOH (60 mL) and stirred at 0°C for 10 min. A 4 M
HCl solution (35 mL, 140 mmol) was then added dropwise and stirred for 30 min at 0°C under
N2. The reaction was then slowly warmed to room temperature and stirred under N2 for 4 h.
Upon completion, the solvent was removed in vacuo to give 46a as a white solid (365 mg, 98%)
97

1

H NMR (D2O) δ 3.25 (m, 1H), 3.15 (t, 6H), 3.10 (t, 2H), 2.09 (m, 4H), 1.72 (m, 4H), 1.39-1.35

(m, 26H); 13C (D2O) δ 58.6, 44.7, 41.9, 36.5, 28.7, 26.6, 26.3, 26.2, 26.0, 25.9, 23.7, 22.9, 22.4.
HRMS (FAB) m/z calc for C21H45N3 (M + H)+ 340.3613, found 340.3693. Elemental Analysis:
C21H48Cl3N3·0.05 H2O theory C: 55.57, H: 10.68, N: 9.26; found C: 55.77, H: 10.65, N: 8.98.
N1-(4-Aminobutyl)-N4-cyclopentadecylbutane-1,4-diamine (46b). (1.53 g, 99%). 1H
NMR (D2O) δ 3.22 (m, 1H), 3.11 (t, 6H), 3.04 (t, 4H), 1.76-1.71 (m, 12H) 1.46-1.28 (m, 26H)
13

C NMR (D2O) δ 60.8, 60.5, 49.4, 46.9, 41.3, 31.4, 29.2, 28.9, 28.8, 28.6, 28.5, 26.4, 25.5, 25.1.

HRMS (FAB) m/z calc for C23H49N3 (M + H)+ 368.3926, found 368.3983. Elemental Analysis:
C23H52Cl3N3·0.05 H2O theory C: 57.32, H: 10.90, N: 8.72; found C: 57.31, H: 10.95, N: 8.52.
N1-(3-aminopropyl)-N3-(cyclopentadecylmethyl)propane-1,3-diamine (47a).
Compound 54a (250 mg, 0.5 mmol) was first dissolved in EtOH (35 mL) and stirred at 0°C for
10 min. A 4 M HCl solution (17 mL, 68 mmol) was then added dropwise and stirred for 30 min
at 0°C under N2. The reaction was then slowly warmed to room temperature and stirred under N2
for 4 h. Upon completion, the solvent was removed in vacuo to give 46a as a white solid (191
mg, 93%) 1H NMR (D2O) δ 3.16 (t, 4H), 3.09 (t, 4H), 2.93 (d, 2H), 2.10 (m, 4H), 1.82 (m, 1H),
1.32 (m, 30H); 13C NMR (D2O) δ 54.7, 47.3, 46.9, 38.7, 36.5, 31.6, 29.2, 28.8, 28.7, 28.6, 28.4,
26.0, 25.8, 24.8. HRMS (FAB) m/z calc for C22H47N3 (M + H)+ 354.3770, found 354.3846.
Elemental Analysis: C22H50N3Cl3•0.15 H2O theory C: 55.32, H: 10.61, N: 8.80; found C: 55.59,
H: 10.85, N: 8.47.
N1-(4-aminobutyl)-N4-(cyclopentadecylmethyl)butane-1,4-diamine (47b). Compound
47b was generated using a procedure similar to that described for 47a. (80 mg, 95%). 1H NMR
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(D2O) δ 3.07 (t, 4H), 3.04 (t, 4H), 2.93 (d, 2H), 1.76 (m, 9H), 1.33 (m, 28H); 13C NMR (D2O) δ
54.6, 49.8, 49.3, 41.2, 36.5, 31.8, 29.3, 29.9, 29.8, 28.7, 28.5, 26.3, 26.0, 25.3, 25.2, 25.0. HRMS
(FAB) m/z calc for C24H51N3 (M + H)+ 382.4083, found 382.4159. Elemental Analysis:
C24H54N3Cl3•0.2 H2O theory C: 56.45, H: 10.74, N: 8.23; found C: 56.48, H: 10.78, N: 8.29.
tert-Butyl (3-((tert-butoxycarbonyl)amino)propyl)(3(cyclopentadecylamino)propyl)carbamate (50a). A solution of diBoc-norspermidine 49a (410
mg, 1.2 mmol) in CH2Cl2 (10 mL) was added dropwise to a solution of cyclopentadecanone 48
(250 mg, 1.1 mmol) in CH2Cl2 (10 mL) and allowed to stir at room temperature for 10 minutes.
Sodium triacetoxyborohydride (1.2 g, 5.6 mmol) and acetic acid (67 mg, 1.1 mmol) were then
added to the solution and allowed to stir at room temperature overnight. Once the reaction was
complete by 1H NMR, the solution was then washed with aq. Na2CO3, and the organic layer was
separated, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. After column
chromatography ((Rf=0.28 (70% hexanes/24% CHCl3/5.9% EtOH/0.1% NH4OH)), 50a was
isolated as a pale yellow oil (450 mg, 75%). 1H NMR (CDCl3) δ 3.25 (t, 4H), 3.10 (t, 2H), 2.62
(m, 3H), 1.67 (m, 4H), 1.47-1.26 (m, 46H); 13C NMR (CDCl3) δ 156.0, 80.3, 79.2, 57.4, 56.9,
44.2, 43.7, 37.7, 36.7, 32.6, 31.7, 28.9, 28.5, 28.3, 27.5, 26.9, 26.8, 26.6, 26.5, 23.5. HRMS
(FAB) m/z calc for C31H61N3O4 (M)+ 540.4662, found 540.4734. Elemental Analysis:
C31H61N3O4·0.05 H2O theory C: 68.35, H: 11.31, N: 7.71; found C: 68.42, H: 11.24, N: 7.86.
tert-Butyl (4-((tert-butoxycarbonyl)amino)butyl)(4-(cyclopentadecylamino)butyl)carbamate (50b). (1.54 g, 54%). 1H (CDCl3) δ 3.18 (t, 6H), 2.59 (t, 2H), 2.52 (m, 1H),
1.55 (m, 4H), 1.51-1.22 (m, 46H); 13C NMR (CDCl3) δ 156.0, 155.5, 79.1, 77.3, 56.8, 47.1, 46.5,
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40.2, 32.7, 28.5, 28.4, 27.7, 27.5, 27.4, 26.8, 26.6, 26.5, 26.2, 25.9, 25.5, 23.6. HRMS (FAB) m/z
calc for C33H65N3O4 (M)+ 568.4975, found 568.5048. Elemental Analysis: C33H65N3O4 theory C:
69.80, H: 11.54, N: 7.40; found C: 69.58, H: 11.64, N: 7.31.
Methylenecyclopentadecane (51). To a solution of methyltriphenylphosphonium iodide
(12 g, 30 mmol) in THF (200 mL) was added dropwise n-BuLi (18.5 mL, 30 mmol) at 0°C. The
suspension was stirred at 0°C until a yellow color persisted, and then cyclopentadecanone, 48,
(2.21 g, 9.8 mmol) was added as a solution in THF (20 mL). The mixture was allowed to warm
to room temperature and stirred overnight. Upon completion, H2O was added to quench any
remaining n-BuLi and any precipitates were filtered off. The filtrate was concentrated in vacuo
and the residue was redissolved in CH2Cl2, washed three times with deionized H2O. The organic
layer was separated, dried over anhydrous Na2SO4, filtered, and then concentrated under reduced
pressure to give a pale red oil. After column chromatography (Rf=0.9, 10% CH2Cl2/90%
hexanes) 51 was isolated as a pale yellow oil (1.5 g, 69%). 1H NMR (CDCl3) δ 4.65 (s, 2H), 1.96
(t, 4H), 1.37 (m, 4H), 1.27-1.25 (m, 20H).51
Cyclopentadecylmethanol (52). A solution of the starting alkene 51 (1.5 g, 6.7 mmol) in
THF (8 mL) was added dropwise to a cooled 1 M solution of BH3-THF (20.2 mL, 20.2 mmol).
The reaction was stirred at 0°C for 1 h and then allowed to stir for 2 h at room temperature.
Excess diborane was decomposed by dropwise addition of water (10 mL). A 3 M solution of
NaOH (10 mL) was then added, followed by dropwise addition of 30% H2O2 (10 mL). The
reaction was stirred for 1 h at room temperature and K2CO3 (100 mg) was then added. The layers
were then separated and the aqueous layer was extracted three times with CH2Cl2, the organic
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layers were pooled, dried over Na2SO4, then filtered and concentrated. After column
chromatography (Rf=0.31, 50% hexanes/50% CH2Cl2) 52 was isolated as a yellow oil (1.2 g,
74%). 1H NMR (CDCl3) δ 3.49 (t, 2H), 1.53 (m, 1H), 1.41-1.22 (m, 28H); 13C NMR (CDCl3) δ
67.0, 39.5, 29.6, 27.5, 27.0, 26.7, 26.6, 26.5, 25.0.
Cyclopentadecanecarbaldehyde (53). To a solution of alcohol 52 (300 mg, 1.25 mmol)
in CH2Cl2 (20 mL) was added PCC (404 mg, 1.87 mmol) at room temperature. The reaction was
monitored by TLC (50% hexanes/50% CH2Cl2) until complete (60 min). Upon reaching
completion, the mixture was then diluted with Et2O, filtered through Celite and concentrated in
vacuo to give aldehyde 53 as a yellow oil that was used without further purification (250 mg
crude). 1H NMR (CDCl3) δ 9.61 (s, 1H), 2.43 (m, 2H), 2.29 (m, 1H), 1.62 (m, 4H), 1.49 (m, 4H),
1.44-1.31 (m, 20H). This aldehyde was found to be unstable and was best used immediately in
subsequent steps.
tert-Butyl (3-((tert-butoxycarbonyl)amino)propyl)(3((cyclopentadecylmethyl)amino)propyl)carbamate (54a).
A solution of diBoc-norspermidine 49a (496 mg, 1.5 mmol) in CH2Cl2 (12 mL) was added
dropwise to a solution of the crude cyclopentadecanecarbaldehyde 53 (310 mg crude) in CH2Cl2
(12 mL) and allowed to stir at room temperature for 10 min. Acetic acid (72 µL, 1.26 mmol) was
then added and the solution was stirred for 20 min, followed by the addition of sodium
triacetoxyborohydride (1.33 g, 6.3 mmol) and stirred at room temperature overnight. Upon
completion, the reaction mixture was washed three times with aq. 10% Na2CO3, the organic
layer was separated, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. After
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column chromatography (Rf=0.25; 94.5% CH2Cl2/5% MeOH/0.5% NH4OH), 54a was isolated as
a pale yellow oil (250 mg, 36% over 2 steps). 1H NMR (CDCl3) δ 3.24 (t, 4H), 3.11 (t, 2H), 2.73
(d, 2H), 2.62 (m, 4H), 2.48 (t, 2H), 1.92 (m, 1H), 1.70 (m, 4H), 1.48-1.26 (m, 46H); 13C NMR
(CDCl3) δ 156.1, 80.1, 79.5, 79.2, 54.6, 54.0, 46.2, 46.1, 44.2, 43.7, 37.4, 36.1, 30.6, 29.0, 28.7,
28.4, 28.2, 27.6, 27.1, 26.9, 26.8, 26.6, 26.5, 24.7, 24.5. HRMS (FAB) m/z calc for C32H63N3O4
(M + H)+ 554.4819, found 554.4894. Elemental Analysis: C32H63N3O4·0.05 H2O theory C:
68.79, H: 11.38, N: 7.52; found C: 68.74, H: 11.30, N: 7.27.
tert-Butyl (4-((tert-butoxycarbonyl)amino)butyl)(4((cyclopentadecylmethyl)amino)butyl)carbamate (54b). Compound 54b was synthesized
using a similar procedure as 54a. (100 mg, 45% over 2 steps). 1H NMR (CDCl3) δ 3.15 (t, 6H),
2.60 (t, 2H), 2.47 (d, 2H), 1.52 (m, 9H), 1.51-1.42 (s, 18H), 1.39-1.23 (m, 28H); 13C NMR
(CDCl3) δ 156.0, 156.6, 79.2, 54.8, 49.8, 46.9, 46.7, 40.3, 36.9, 31.0, 28.5, 28.4, 27.6, 27.4, 27.0,
26.8, 26.7, 26.5, 24.8. HRMS (FAB) m/z calc for C34H67N3O4 (M + H)+ 582.5132, found
582.5213. Elemental Analysis: C34H67N3O4•0.05 H2O theory C: 69.59, H: 11.53, N: 7.16; found
C: 69.59, H: 11.24, N: 7.22.
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H NMR Spectrum of 6b in D2O. (Scheme I-1)
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H NMR Spectrum of 6b in D2O.

(Scheme I-2)
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H NMR Spectrum of 6b in D2O.

(Scheme I-4)
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C NMR Spectrum of 6b in D2O.

(Scheme I-4)

•6 HCl

107

1

H NMR Spectrum of 7b in D2O.

•6 HCl
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C NMR Spectrum of 7b in D2O.
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H NMR Spectrum of 8b in D2O.
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C NMR Spectrum of 8b in D2O.
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H NMR Spectrum of 10 in CDCl3.
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H NMR Spectrum of 11 in CDCl3.
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H NMR Spectrum of 12 in CDCl3.
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H NMR Spectrum of 13 in CDCl3.
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H NMR Spectrum of 14 in D2O.
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H NMR Spectrum of 15 in CDCl3.
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C NMR Spectrum of 15 in CDCl3.
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H NMR Spectrum of 16 in CDCl3.
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C NMR Spectrum of 16 in CDCl3.
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H NMR Spectrum of 17 in CDCl3.
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H NMR Spectrum of 18 in CDCl3.
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H NMR Spectrum of 19 in CDCl3.
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H NMR Spectrum of 20 in CDCl3.
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H NMR Spectrum of 21 in CDCl3.
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H NMR Spectrum of 22 in CDCl3.
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H NMR Spectrum of 23 in CDCl3
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H NMR Spectrum of 24 in CDCl3
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H NMR Spectrum of 25 in CDCl3.
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H NMR Spectrum of 26 in CDCl3.
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H NMR Spectrum of 27 in CDCl3.
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H NMR Spectrum of 28 in CDCl3.

(Scheme I-3)
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H NMR Spectrum of 28 in CDCl3.

(Scheme I-4)
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C NMR Spectrum of 28 in CDCl3.

(Scheme I-4)
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H NMR Spectrum of 29 in CDCl3.

(Scheme I-4)
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C NMR Spectrum of 29 in CDCl3.

(Scheme I-4)
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H NMR Spectrum of 30 in CDCl3.
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C NMR Spectrum of 30 in CDCl3.
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H NMR Spectrum of 31 in CDCl3.
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C NMR Spectrum of 31 in CDCl3.
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H NMR Spectrum of 33a in D2O.
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C NMR Spectrum of 33a in D2O.
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H NMR Spectrum of 33b in D2O.
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C NMR Spectrum of 33b in D2O.
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H NMR Spectrum of 34a in D2O.
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C NMR Spectrum of 34a in D2O.
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H NMR Spectrum of 34b in D2O.
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C NMR Spectrum of 34b in D2O.
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H NMR Spectrum of 35 in D2O.
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H NMR Spectrum of 38a in CDCl3.
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C NMR Spectrum of 38a in CDCl3.
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H NMR Spectrum of 38b in CDCl3.
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C NMR Spectrum of 38b in CDCl3.
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H NMR Spectrum of 40a in CDCl3.
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C NMR Spectrum of 40a in CDCl3.
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H NMR Spectrum of 40b in CDCl3.
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C NMR Spectrum of 40b in CDCl3.
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H NMR Spectrum of 46a in D2O.
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C NMR Spectrum of 46a in D2O.

•3 HCl

161

1

H NMR Spectrum of 46b in D2O.
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C NMR Spectrum of 46b in D2O.
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H NMR Spectrum of 47a in D2O.
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C NMR Spectrum of 47a in D2O.
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H NMR Spectrum of 47b in D2O.
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C NMR Spectrum of 47b in D2O.
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H NMR Spectrum of 50a in CDCl3.
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C NMR Spectrum of 50a in CDCl3.
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H NMR Spectrum of 50b in CDCl3.
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C NMR Spectrum of 50b in CDCl3.
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H NMR Spectrum of 51 in CDCl3.
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H NMR Spectrum of 52 in CDCl3.
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C NMR Spectrum of 52 in CDCl3.
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H NMR Spectrum of 53 in CDCl3.
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H NMR Spectrum of 54a in CDCl3.
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C NMR Spectrum of 54a in CDCl3.
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H NMR Spectrum of 54b in CDCl3.
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C NMR Spectrum of 54b in CDCl3.
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